{"gene":"TNFRSF11B","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":1997,"finding":"Osteoprotegerin (OPG/TNFRSF11B) was identified as a novel secreted glycoprotein member of the TNF receptor superfamily that inhibits osteoclast differentiation from precursor cells in a dose-dependent manner. Hepatic overexpression in transgenic mice caused osteopetrosis with decreased osteoclast numbers, and administration of recombinant OPG to normal mice replicated these effects. OPG also blocked ovariectomy-associated bone loss in rats.","method":"Transgenic mouse overexpression, recombinant protein administration in vivo, in vitro osteoclast differentiation assay","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal in vivo and in vitro methods in founding discovery paper, replicated broadly","pmids":["9108485"],"is_preprint":false},{"year":1997,"finding":"OPG/OCIF was purified from human fibroblast conditioned medium as a heparin-binding glycoprotein existing as a monomer (~60 kDa) and homodimer (~120 kDa). It specifically inhibited osteoclastogenesis driven by three distinct signaling pathways (vitamin D3, PTH, IL-11) without inhibiting mature osteoclast bone-resorbing activity, establishing it as a specific inhibitor of osteoclast development rather than function.","method":"Protein purification, in vitro osteoclastogenesis assay with multiple stimuli","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — purified protein with multiple functional assays, replicated by independent group","pmids":["9168977"],"is_preprint":false},{"year":1998,"finding":"OPG/OCIF was shown to inhibit osteoclastogenesis by binding to a high-affinity site on osteoblastic stromal cells (ST2 line), blocking the cell-to-cell signal required for osteoclast progenitor differentiation. A single class of high-affinity OPG-binding sites appeared on ST2 cells in response to 1,25-dihydroxyvitamin D3, and an antibody blocking OPG binding to these sites abolished OPG's biological activity.","method":"Binding assay on stromal cells, antibody blockade, osteoclastogenesis coculture assay","journal":"Endocrinology","confidence":"High","confidence_rationale":"Tier 2 — receptor binding characterization with functional antibody blockade, replicated","pmids":["9492069"],"is_preprint":false},{"year":1998,"finding":"Osteoclast differentiation factor (ODF/RANKL) was identified as the ligand for OPG/OCIF by expression cloning from mouse stromal cell cDNA library. OPG abolished OCL formation induced by soluble ODF, establishing OPG as a decoy receptor that blocks RANKL-RANK signaling to prevent osteoclastogenesis.","method":"Expression cloning, recombinant protein functional assay, OPG neutralization of ODF activity","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1-2 — ligand identified by expression cloning with direct functional neutralization, foundational paper","pmids":["9520411"],"is_preprint":false},{"year":1998,"finding":"OPG-deficient mice develop early-onset osteoporosis with severe trabecular and cortical bone porosity and high fracture incidence, demonstrating OPG is a critical regulator of postnatal bone mass. Unexpectedly, OPG-/- mice also develop medial calcification of the aorta and renal arteries, revealing OPG's role in protecting large arteries from calcification.","method":"Knockout mouse generation, skeletal phenotyping, histology, arterial pathology assessment","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function mouse model with defined skeletal and vascular phenotypes, highly replicated","pmids":["9573043"],"is_preprint":false},{"year":1998,"finding":"OPG was identified as a receptor for the cytotoxic ligand TRAIL, binding TRAIL with an affinity of ~3 nM. OPG-Fc inhibits TRAIL-induced apoptosis of Jurkat cells, and conversely TRAIL blocks OPG's anti-osteoclastogenic activity, revealing cross-regulatory mechanisms between bone remodeling and apoptosis pathways.","method":"Binding affinity measurement (Fc-fusion proteins), TRAIL-induced apoptosis assay, competitive inhibition","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — direct binding affinity measured, functional competition assay, replicated extensively","pmids":["9603945"],"is_preprint":false},{"year":1998,"finding":"OCIF/OPG directly inhibits bone-resorbing activity of isolated mature osteoclasts in an ODF-independent manner. An OPG-binding protein of 140 kDa was detected on the osteoclast plasma membrane. OPG did not affect cathepsin K or carbonic anhydrase II mRNA levels but reduced/disrupted F-actin ring formation in osteoclasts, a cytoskeletal structure required for bone resorption.","method":"Isolated osteoclast bone resorption assay, ligand binding on osteoclast membrane, F-actin staining","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 2 — direct functional assay on purified osteoclasts with mechanistic readout (F-actin ring disruption)","pmids":["9790989"],"is_preprint":false},{"year":1999,"finding":"Genetic deletion of OPGL (RANKL) in mice caused severe osteopetrosis and complete absence of osteoclasts, confirming OPG's ligand RANKL is an essential osteoclast differentiation factor in vivo and that the OPG/RANKL system is the dominant regulator of osteoclastogenesis.","method":"Gene knockout in mice, skeletal phenotyping, osteoclast enumeration","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo establishing pathway position, replicated and foundational","pmids":["9950424"],"is_preprint":false},{"year":2002,"finding":"A homozygous 3-bp in-frame deletion in exon 3 of TNFRSF11B (loss of aspartate residue) was found in patients with idiopathic hyperphosphatasia. Recombinant mutant OPG expressed in HEK cells was secreted but failed to suppress bone resorption in vitro, whereas wild-type OPG suppressed it, confirming this as an inactivating mutation affecting RANKL-binding function.","method":"Genetic sequencing, recombinant protein expression in HEK cells, in vitro bone resorption assay","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 1-2 — functional mutagenesis validated in bone resorption assay, genotype-phenotype confirmed","pmids":["12189164"],"is_preprint":false},{"year":2002,"finding":"Juvenile Paget's disease in two Navajo patients results from homozygous deletion of TNFRSF11B (~100 kb) at chromosome 8q24.2. Serum OPG was undetectable and soluble RANKL was markedly elevated, directly demonstrating that OPG deficiency causes uncontrolled RANKL-driven osteoclastogenesis and rapid bone turnover in humans.","method":"PCR and Southern blotting of genomic DNA, sequence-tagged site mapping, ELISA for serum OPG and sRANKL","journal":"The New England journal of medicine","confidence":"High","confidence_rationale":"Tier 2 — complete gene deletion with direct measurement of OPG absence and RANKL elevation","pmids":["12124406"],"is_preprint":false},{"year":2002,"finding":"OPG is produced by prostate cancer cells and functions as a survival factor by inhibiting TRAIL-induced apoptosis. High endogenous OPG production correlated with resistance to TRAIL-induced apoptosis, and this protection was reversed by 100-fold molar excess of RANKL (which competes for OPG binding), establishing OPG as a cancer cell survival factor via TRAIL neutralization.","method":"TRAIL apoptosis assay, OPG ELISA, competitive inhibition with RANKL, multiple prostate cancer cell lines","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — functional assay with competitive reversal in multiple cell lines","pmids":["11912131"],"is_preprint":false},{"year":2002,"finding":"Multiple myeloma cells bind, internalize, and degrade OPG through a mechanism dependent on OPG interaction with heparan sulfates on myeloma cell surfaces, providing a mechanism for reduced OPG levels in myeloma bone marrow and contributing to myeloma-associated bone destruction.","method":"OPG binding and internalization assays on myeloma cells, heparan sulfate competition, degradation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of OPG internalization with heparan sulfate dependence established","pmids":["12351414"],"is_preprint":false},{"year":2002,"finding":"PTH stimulates RANKL gene transcription and mRNA stability while potently suppressing OPG mRNA in stromal/osteoblastic cells via protein kinase A (PKA) activation. The transcription factor CREB is required for PTH stimulation of RANKL; dominant-negative CREB and c-fos reduced PTH suppression of OPG, establishing a PKA-CREB pathway as the mechanism for PTH-mediated regulation of the RANKL/OPG axis.","method":"PKA inhibition, dominant-negative CREB/c-fos expression, luciferase reporter assay, mRNA stability assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1-2 — multiple epistasis experiments with dominant-negative constructs establishing pathway mechanism","pmids":["12364326"],"is_preprint":false},{"year":2003,"finding":"Homozygous mutations in TNFRSF11B were found in affected members of six of nine families with idiopathic hyperphosphatasia. Four of six mutations occurred in the cysteine-rich ligand-binding domain, predicted to disrupt OPG-RANKL binding. Cysteine missense mutations causing major disruption of the ligand-binding region correlated with severe phenotype, while non-cysteine or C-terminal mutations caused milder phenotypes, establishing a genotype-phenotype relationship for TNFRSF11B domain function.","method":"Genomic DNA sequencing, clinical phenotype correlation","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 3 — genotype-phenotype mapping predicts domain function without direct in vitro reconstitution for all mutations","pmids":["14672344"],"is_preprint":false},{"year":2003,"finding":"PTH differentially regulates RANKL and OPG expression across osteoblast differentiation stages: PTH maximally inhibits OPG in early osteoblasts (day 14) and maximally upregulates RANKL in mature osteoblasts (days 21-28). PTH-induced changes in RANKL/OPG ratio at day 14 increased TRACP+ cell numbers 5.6-fold in coculture, demonstrating that stage-specific PTH regulation of RANKL and OPG has functional osteoclastogenic consequences.","method":"qRT-PCR at multiple osteoblast differentiation stages, osteoclast coculture assay with TRACP staining","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — quantitative gene expression across differentiation stages linked to functional osteoclastogenesis readout","pmids":["14969393"],"is_preprint":false},{"year":2004,"finding":"Local OPG gene transfer (via HVJ envelope vector carrying pcDNA3.1-mOPG) to the periodontal tissue of rats significantly inhibited osteoclastogenesis and reduced experimental orthodontic tooth movement, demonstrating that OPG protein produced locally can neutralize RANKL activity and block osteoclast-mediated bone resorption in vivo.","method":"In vivo gene transfer, OPG protein production confirmed in vitro, osteoclast enumeration, tooth movement measurement","journal":"Journal of dental research","confidence":"High","confidence_rationale":"Tier 2 — in vivo gene delivery with functional bone resorption and tooth movement readouts","pmids":["15557398"],"is_preprint":false},{"year":2004,"finding":"OPG and RANK show expression in both internal and external enamel epithelium and dental papilla mesenchyme during murine odontogenesis, while RANKL is expressed in pre-osteogenic mesenchymal cells near developing tooth germs. Addition of exogenous OPG to tooth primordia explant cultures delayed tooth development and reduced mineralization, establishing a functional role for OPG in coordinating odontogenesis and osteogenesis.","method":"In situ hybridization/expression analysis during odontogenesis, OPG addition to organ culture explants","journal":"Journal of dental research","confidence":"Medium","confidence_rationale":"Tier 2-3 — expression pattern with functional exogenous OPG treatment in explant culture","pmids":["14981127"],"is_preprint":false},{"year":2004,"finding":"RANKL stimulates matrix calcification, nodule formation, alkaline phosphatase activity, and expression of osteocalcin in cultured human aortic valve myofibroblasts, and increases DNA binding of cbfa-1. OPG expression is significantly lower in calcific aortic stenosis than controls, suggesting the RANKL-OPG pathway regulates valvular calcification by promoting osteoblast-like transition of valve cells.","method":"Immunohistochemistry on human valves, RANKL stimulation of cultured myofibroblasts, alkaline phosphatase assay, cbfa-1 DNA binding assay","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 — direct RANKL stimulation with functional calcification and osteogenic gene readouts in primary cells","pmids":["14734048"],"is_preprint":false},{"year":2005,"finding":"A truncating TNFRSF11B mutation (homozygous insertion/deletion in exon 5) predicts protein truncation at amino acid 325. Western blotting and ELISA after transient overexpression showed the mutant protein lacks homodimerization (C-terminal domain required for this) and has decreased RANKL-binding capacity, demonstrating that the C-terminal domain of OPG is required for homodimerization and full functional RANKL antagonism.","method":"Western blotting, ELISA, transient overexpression of wild-type vs. truncated OPG","journal":"Bone","confidence":"High","confidence_rationale":"Tier 1-2 — direct biochemical demonstration that C-terminal truncation abolishes homodimerization and reduces RANKL binding","pmids":["15777670"],"is_preprint":false},{"year":2007,"finding":"The TNFRSF11B 'Balkan' mutation (966_969delTGACinsCTT) deletes 79 C-terminal amino acids including a cysteine residue necessary for homodimerization. Despite elevated circulating immunoreactive OPG, the truncated monomer cannot form homodimers, and soluble RANKL is persistently elevated, demonstrating that OPG homodimerization via C-terminal cysteine is required for effective RANKL inhibition in vivo.","method":"TNFRSF11B sequencing, serum OPG and sRANKL ELISA, structural prediction of homodimerization requirement","journal":"Journal of bone and mineral research","confidence":"Medium","confidence_rationale":"Tier 2-3 — in vivo biochemical data (elevated monomeric OPG with impaired function) consistent with homodimerization requirement","pmids":["17352649"],"is_preprint":false},{"year":2008,"finding":"IL-6 and PGE2 produced by mechanically loaded osteoblasts induce a decrease in OPG expression (but not RANKL), and IL-6 neutralizing antibodies and piroxicam block this OPG decrease, establishing that mechanical compression-induced IL-6 and PGE2 downregulate OPG to increase the RANKL/OPG ratio in osteoblasts.","method":"Compression model of primary osteoblasts, neutralizing antibodies, COX inhibitor, real-time PCR, ELISA","journal":"Osteoarthritis and cartilage","confidence":"Medium","confidence_rationale":"Tier 2 — cytokine neutralization identifies IL-6/PGE2 as mediators of OPG suppression under mechanical load","pmids":["18974013"],"is_preprint":false},{"year":2009,"finding":"OPG binds membranous RANKL on cells and undergoes internalization through the clathrin pathway prior to proteasomal and/or lysosomal degradation. This OPG internalization process reduces the half-life of RANKL, revealing a reciprocal mechanism by which OPG-RANKL binding leads to co-degradation of both molecules.","method":"Internalization assay, clathrin pathway inhibition, degradation assays","journal":"The Keio journal of medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — mechanistic pathway (clathrin-mediated internalization) identified for OPG-RANKL complex","pmids":["19398882"],"is_preprint":false},{"year":2009,"finding":"OPG-Fc (OPG without the heparin-binding domain) treatment of OA chondrocytes significantly stimulated MMP-13 and PAR-2 production, revealing that OPG has RANKL-independent signaling in chondrocytes that promotes catabolic factor expression, a pathway distinct from its role in bone remodeling.","method":"OPG-Fc treatment of primary human OA chondrocytes, cytokine measurement by ELISA, flow cytometry for RANK/RANKL","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2-3 — direct OPG treatment with specific catabolic readouts in primary human cells","pmids":["19762475"],"is_preprint":false},{"year":2009,"finding":"DNA methylation silences OPG expression in cancer cells: OPG promoter CpG dinucleotides are highly methylated in OPG-silenced cancer cell lines, with reduced H3K4me3 and increased H3K27me3 at the OPG gene. Recombinant OPG reduced cancer cell growth through apoptosis, establishing epigenetic repression as a mechanism of OPG silencing in carcinoma.","method":"Bisulfite sequencing, ChIP for histone modifications, recombinant OPG apoptosis assay, cDNA microarray","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — epigenetic mechanism identified with ChIP and functional rOPG apoptosis assay","pmids":["19565568"],"is_preprint":false},{"year":2010,"finding":"TGFβ-inducible early gene-1 (TIEG/KLF10) directly binds to the OPG promoter and represses its transcription in osteoblasts. Transient ChIP assays showed TIEG occupancy at the OPG promoter, and site-directed mutagenesis identified two Sp-1 binding sites within a 200 bp region as required for TIEG-mediated repression, explaining why TIEG KO osteoblasts have increased OPG and reduced osteoclastogenesis support.","method":"ChIP assay, luciferase reporter with OPG promoter deletion constructs, site-directed mutagenesis, TIEG KO osteoblasts","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 — ChIP demonstrates direct binding, mutagenesis identifies specific Sp-1 sites, supported by KO model","pmids":["20059964"],"is_preprint":false},{"year":2014,"finding":"A heterozygous read-through mutation (c.1205A>T; p.Stop402Leu) in TNFRSF11B was identified in a family with dominantly inherited early-onset osteoarthritis with chondrocalcinosis. The mutant OPG showed enhanced capacity to inhibit osteoclastogenesis and bone resorption in a bone resorption cell-based assay, establishing this as a gain-of-function mutation in TNFRSF11B that causes OA.","method":"Exome sequencing, linkage analysis, bone resorption cell-based assay comparing wild-type vs. mutant OPG","journal":"Annals of the rheumatic diseases","confidence":"Medium","confidence_rationale":"Tier 2 — functional assay demonstrates gain-of-function, supported by family genetics","pmids":["24743232"],"is_preprint":false},{"year":2018,"finding":"DNA methylation inversely regulates OPG and RANKL expression in osteoporotic bone: OPG promoter CpG methylation is higher and OPG expression lower in osteoporotic fracture bone, while RANKL promoter methylation is lower and RANKL expression higher, demonstrating that promoter methylation is a major epigenetic switch controlling the RANKL/OPG ratio in bone pathophysiology.","method":"Bisulfite sequencing of promoter CpG islands, qRT-PCR of OPG and RANKL in bone biopsies","journal":"International journal of medical sciences","confidence":"Medium","confidence_rationale":"Tier 3 — correlative methylation-expression analysis in human bone tissue without functional validation","pmids":["30443169"],"is_preprint":false},{"year":2020,"finding":"TNFRSF11B overexpression in gastric cancer cells promotes proliferation, migration, invasion, and tumorigenesis. Mechanistically, TNFRSF11B directly binds GSK-3β (detected by co-immunoprecipitation), upregulates GSK-3β phosphorylation, and consequently increases nuclear β-catenin and downstream Wnt/β-catenin target gene expression, identifying a non-canonical RANKL-independent oncogenic signaling role for TNFRSF11B.","method":"Co-immunoprecipitation, immunofluorescence for nuclear β-catenin, Western blotting, in vitro and in vivo tumor assays","journal":"International journal of biological sciences","confidence":"Medium","confidence_rationale":"Tier 2-3 — Co-IP identifies GSK-3β interaction with functional Wnt pathway readout, single lab","pmids":["32398963"],"is_preprint":false},{"year":2022,"finding":"TNFRSF11B overexpression in primary human articular chondrocytes (3D chondrogenic model) strongly upregulates MMP13, COL2A1, COL1A1, RUNX2, ASPN, OGN, and BMP6 (9-fold), while RANK and RANKL expression remained unchanged, indicating TNFRSF11B drives chondrocyte-to-osteoblast transition in OA cartilage through previously unknown downstream pathways independent of the OPG/RANK/RANKL triad.","method":"Lentiviral overexpression in primary chondrocytes, 3D chondrogenic culture, RT-qPCR, immunohistochemistry, ELISA, Alcian blue staining","journal":"Rheumatology (Oxford, England)","confidence":"Medium","confidence_rationale":"Tier 2 — lentiviral overexpression in 3D primary cell model with multiple downstream readouts, single lab","pmids":["33989379"],"is_preprint":false},{"year":2022,"finding":"Fluid shear stress (FSS) promotes OPG expression and inhibits RANKL expression in MLO-Y4 osteocytes via Piezo1 mechanosensitive ion channel and NOTCH3 signaling. Blocking Piezo1 with GsMTx4 reversed FSS effects on OPG and RANKL, establishing a Piezo1-NOTCH3 pathway as a mechanotransduction mechanism regulating OPG production.","method":"Fluid shear stress apparatus, Piezo1 blocker (GsMTx4), RT-PCR and protein expression in osteocyte cell line","journal":"Channels (Austin, Tex.)","confidence":"Medium","confidence_rationale":"Tier 2-3 — pharmacological blockade of Piezo1 with OPG/RANKL readout, single lab with mechanistic pathway identification","pmids":["35754337"],"is_preprint":false},{"year":2008,"finding":"OPG and TRAIL co-localize at sites of vascular calcification in Mönckeberg's sclerosis and atherosclerosis, with OPG expressed surrounding calcified areas in medial and neointimal layers where apoptosis also occurs, suggesting OPG is expressed at vascular calcification sites to regulate both apoptosis (via TRAIL) and osteoclast-like differentiation.","method":"Immunohistochemistry, in situ hybridization, in situ ligation apoptosis assay on human arterial specimens","journal":"The Journal of clinical endocrinology and metabolism","confidence":"Medium","confidence_rationale":"Tier 3 — localization study in human tissue with mechanistic implication but no direct functional experiment","pmids":["15292354"],"is_preprint":false},{"year":2008,"finding":"Myeloma-derived DKK1 (a Wnt inhibitor) abolishes Wnt3a-induced OPG mRNA and protein production by mouse and human osteoblasts, while simultaneously enhancing RANKL expression, providing a molecular mechanism by which myeloma cells disrupt the Wnt-regulated OPG/RANKL balance to promote osteoclastogenesis and bone lesions.","method":"Recombinant DKK1 treatment, coculture of osteoblasts with MM cells, Wnt3a stimulation, OPG/RANKL mRNA and protein measurement, bone marrow sera from MM patients","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (recombinant protein, coculture, patient samples) establishing DKK1→Wnt→OPG mechanism","pmids":["18305214"],"is_preprint":false}],"current_model":"TNFRSF11B (osteoprotegerin/OPG) is a secreted homodimeric decoy receptor of the TNF receptor superfamily that inhibits osteoclastogenesis by binding RANKL (preventing RANKL-RANK interaction) and also neutralizes TRAIL-induced apoptosis; its activity is regulated by PTH via a PKA-CREB pathway, by transcription factor TIEG1 (KLF10) binding Sp-1 sites in its promoter, by epigenetic promoter methylation, by Wnt signaling, and by mechanical load via Piezo1-NOTCH3; OPG homodimerization through C-terminal cysteine residues is required for full RANKL-binding activity, loss-of-function TNFRSF11B mutations cause juvenile Paget's disease/idiopathic hyperphosphatasia through unrestrained RANKL-driven osteoclastogenesis, and beyond bone OPG also protects arteries from calcification, while in cancer contexts TNFRSF11B can activate Wnt/β-catenin signaling through direct GSK-3β interaction and drive chondrocyte-to-osteoblast transition through RANK/RANKL-independent downstream pathways."},"narrative":{"teleology":[{"year":1997,"claim":"The discovery that OPG is a secreted TNF receptor superfamily member that inhibits osteoclast differentiation in vitro and causes osteopetrosis when overexpressed in vivo established the existence of a soluble osteoclastogenesis inhibitor.","evidence":"Transgenic mouse overexpression, recombinant protein administration, and in vitro osteoclast differentiation assays; independently confirmed by purification from fibroblast conditioned medium","pmids":["9108485","9168977"],"confidence":"High","gaps":["Identity of OPG's ligand was unknown","Mechanism of osteoclastogenesis inhibition (direct vs. indirect) was unresolved","Physiological relevance of endogenous OPG was not yet tested by loss-of-function"]},{"year":1998,"claim":"Identification of RANKL as the OPG ligand, and the demonstration that OPG binds TRAIL, established OPG as a dual decoy receptor integrating bone remodeling and apoptosis pathways.","evidence":"Expression cloning identified ODF/RANKL as OPG's osteoblast-expressed ligand; independent binding studies showed OPG binds TRAIL at ~3 nM and blocks TRAIL-induced apoptosis","pmids":["9520411","9603945","9492069"],"confidence":"High","gaps":["Whether OPG-TRAIL interaction has physiological significance in vivo was unclear","Relative affinities and competitive dynamics between RANKL and TRAIL binding to OPG were not fully quantified"]},{"year":1998,"claim":"OPG knockout mice developing severe osteoporosis and arterial calcification demonstrated that endogenous OPG is essential for maintaining both bone mass and vascular integrity in vivo.","evidence":"OPG-/- mice with skeletal phenotyping and arterial histopathology","pmids":["9573043"],"confidence":"High","gaps":["Mechanism of OPG-mediated vascular protection was unknown","Whether arterial calcification reflects direct OPG action on vascular cells or indirect bone-vascular coupling was unresolved"]},{"year":1998,"claim":"Beyond blocking osteoclast differentiation, OPG was shown to directly inhibit bone-resorbing activity of mature osteoclasts by disrupting F-actin ring formation, via a 140 kDa binding protein on the osteoclast surface, revealing a post-differentiation function.","evidence":"Isolated osteoclast bone resorption assay with F-actin staining and ligand-binding detection","pmids":["9790989"],"confidence":"High","gaps":["Identity of the 140 kDa OPG-binding protein on osteoclasts was not determined","Whether this direct osteoclast effect is RANKL-dependent or independent was not resolved"]},{"year":2002,"claim":"Human genetic studies linked loss-of-function TNFRSF11B mutations to juvenile Paget's disease, with complete gene deletion causing undetectable serum OPG and elevated RANKL, providing definitive proof that OPG is the critical RANKL antagonist in human bone homeostasis.","evidence":"Genomic deletion mapping, point mutation identification, serum OPG/sRANKL ELISA, and functional testing of mutant OPG in bone resorption assays","pmids":["12124406","12189164"],"confidence":"High","gaps":["Full genotype-phenotype spectrum across different TNFRSF11B domains was incomplete","Whether heterozygous carriers have intermediate bone phenotypes was not established"]},{"year":2002,"claim":"The PTH-PKA-CREB pathway was identified as a major transcriptional regulator of the RANKL/OPG ratio, with PTH suppressing OPG through CREB-dependent mechanisms, explaining how hormonal signals modulate osteoclastogenesis via OPG.","evidence":"PKA inhibition, dominant-negative CREB/c-fos constructs, and reporter assays in osteoblastic cells; differentiation-stage analysis showed maximal OPG suppression in early osteoblasts","pmids":["12364326","14969393"],"confidence":"High","gaps":["Direct CREB binding to the OPG promoter was not demonstrated by ChIP","Whether other PTH-responsive transcription factors contribute was unclear"]},{"year":2002,"claim":"OPG was found to function as a cancer cell survival factor by neutralizing TRAIL-induced apoptosis in prostate cancer, while myeloma cells actively degrade OPG via heparan sulfate-dependent internalization, revealing pathological exploitation of OPG in cancer.","evidence":"TRAIL apoptosis assays with RANKL competition in prostate cancer lines; OPG binding/internalization and degradation assays on myeloma cells","pmids":["11912131","12351414"],"confidence":"High","gaps":["Whether OPG-mediated TRAIL neutralization is relevant to other cancer types in vivo was untested","Structural basis for OPG-heparan sulfate interaction was unknown"]},{"year":2005,"claim":"Truncation mutations removing the C-terminal domain abolished OPG homodimerization and reduced RANKL-binding capacity, establishing that C-terminal cysteine-mediated dimerization is required for full functional activity.","evidence":"Western blotting and ELISA of wild-type vs. truncated OPG after transient expression; confirmed by Balkan mutation analysis showing elevated monomeric OPG with impaired function in vivo","pmids":["15777670","17352649"],"confidence":"High","gaps":["Crystal structure of the OPG homodimer was lacking","Precise stoichiometry of OPG-RANKL complex was not determined"]},{"year":2008,"claim":"Wnt signaling was identified as a positive regulator of OPG production in osteoblasts, with myeloma-derived DKK1 abolishing Wnt3a-induced OPG expression while enhancing RANKL, providing a molecular mechanism for myeloma bone disease.","evidence":"Recombinant DKK1 and Wnt3a treatment of osteoblasts, coculture with myeloma cells, and patient bone marrow sera analysis","pmids":["18305214"],"confidence":"High","gaps":["Which specific Wnt pathway components (TCF/LEF binding sites) control OPG transcription was not mapped","Whether other Wnt antagonists similarly suppress OPG was untested"]},{"year":2010,"claim":"TIEG/KLF10 was shown to directly bind the OPG promoter at Sp-1 sites and repress transcription, identifying a specific transcription factor–promoter interaction that fine-tunes OPG levels in osteoblasts.","evidence":"ChIP assay demonstrating TIEG occupancy, luciferase reporter with deletion constructs, and site-directed mutagenesis of Sp-1 sites","pmids":["20059964"],"confidence":"High","gaps":["Whether TIEG regulation of OPG operates in non-osteoblast lineages was unknown","Interaction with other Sp-1 site-binding factors was not examined"]},{"year":2014,"claim":"A gain-of-function read-through mutation in TNFRSF11B causing dominantly inherited early-onset osteoarthritis with chondrocalcinosis expanded the disease spectrum beyond loss-of-function bone disease, revealing that excessive OPG activity also has pathological consequences.","evidence":"Exome sequencing with linkage analysis, and functional bone resorption assay showing enhanced anti-resorptive activity of mutant OPG","pmids":["24743232"],"confidence":"Medium","gaps":["Mechanism by which enhanced OPG activity causes chondrocalcinosis was not determined","Whether the extended C-terminal sequence gains new binding properties was untested"]},{"year":2020,"claim":"A RANKL-independent oncogenic function was identified in which TNFRSF11B directly binds GSK-3β, enhances its phosphorylation, and activates Wnt/β-catenin signaling in gastric cancer cells.","evidence":"Co-immunoprecipitation of OPG with GSK-3β, nuclear β-catenin quantification, and in vitro/in vivo tumor assays","pmids":["32398963"],"confidence":"Medium","gaps":["GSK-3β interaction awaits reciprocal validation and domain mapping","Whether this occurs in non-cancer cells is unknown","Mechanism by which a secreted protein accesses intracellular GSK-3β was not explained"]},{"year":2022,"claim":"Mechanotransduction inputs were connected to OPG regulation through the Piezo1-NOTCH3 axis in osteocytes, and RANKL-independent downstream effects of OPG overexpression in chondrocytes (driving osteoblast-like gene programs) were identified, broadening OPG's functional repertoire beyond RANKL sequestration.","evidence":"Fluid shear stress with Piezo1 blocker GsMTx4 in osteocyte cell line; lentiviral OPG overexpression in 3D primary chondrocyte culture with RT-qPCR for osteogenic markers","pmids":["35754337","33989379"],"confidence":"Medium","gaps":["NOTCH3 pathway intermediates connecting Piezo1 to OPG transcription were not mapped","The receptor mediating RANKL-independent OPG signaling in chondrocytes is unknown","In vivo validation of the Piezo1-OPG axis in bone loading is lacking"]},{"year":null,"claim":"Key unresolved questions include the structural basis of OPG homodimerization and RANKL/TRAIL dual binding, the identity of the receptor mediating RANKL-independent OPG signaling in chondrocytes and vascular cells, and the mechanism by which secreted OPG accesses intracellular GSK-3β in cancer contexts.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal structure of the OPG homodimer or OPG-RANKL complex exists","RANKL-independent OPG receptor in chondrocytes/vasculature is unidentified","GSK-3β interaction mechanism requires validation that OPG is internalized or acts before secretion"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,3,5,6]},{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[3,5]},{"term_id":"GO:0140313","term_label":"molecular sequestering activity","supporting_discovery_ids":[3,5,10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,4,9,15]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[30]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,27,31]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[5,10,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,13,25]}],"complexes":[],"partners":["TNFSF11","TNFSF10","GSK3B","PIEZO1","KLF10","DKK1"],"other_free_text":[]},"mechanistic_narrative":"TNFRSF11B (osteoprotegerin/OPG) is a secreted homodimeric decoy receptor of the TNF receptor superfamily that functions as a master negative regulator of osteoclastogenesis by sequestering RANKL and preventing its engagement with RANK on osteoclast precursors [PMID:9108485, PMID:9520411]. OPG also binds TRAIL with nanomolar affinity and inhibits TRAIL-induced apoptosis, linking bone remodeling to cell survival signaling in both normal and cancer contexts [PMID:9603945, PMID:11912131]. Homodimerization through C-terminal cysteine residues is required for full RANKL-binding activity, and OPG transcription is regulated by a PKA-CREB pathway downstream of PTH, by the transcriptional repressor TIEG/KLF10 acting through Sp-1 sites, by Wnt signaling, by promoter CpG methylation, and by mechanotransduction via Piezo1-NOTCH3 [PMID:15777670, PMID:12364326, PMID:20059964, PMID:18305214, PMID:35754337]. Loss-of-function mutations in TNFRSF11B cause juvenile Paget's disease (idiopathic hyperphosphatasia) through unrestrained RANKL-driven osteoclastogenesis, and OPG-deficient mice additionally develop arterial calcification, establishing OPG as a critical regulator of both bone mass and vascular integrity [PMID:12124406, PMID:9573043]."},"prefetch_data":{"uniprot":{"accession":"O00300","full_name":"Tumor necrosis factor receptor superfamily member 11B","aliases":["Osteoclastogenesis inhibitory factor","Osteoprotegerin"],"length_aa":401,"mass_kda":46.0,"function":"Acts as a decoy receptor for TNFSF11/RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local ratio between TNFSF11 and TNFRSF11B. May also play a role in preventing arterial calcification. May act as decoy receptor for TNFSF10/TRAIL and protect against apoptosis. TNFSF10/TRAIL binding blocks the inhibition of osteoclastogenesis","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/O00300/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TNFRSF11B","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TNFRSF11B","total_profiled":1310},"omim":[{"mim_id":"619820","title":"ATONAL bHLH TRANSCRIPTION FACTOR 8; ATOH8","url":"https://www.omim.org/entry/619820"},{"mim_id":"612113","title":"BONE MINERAL DENSITY QUANTITATIVE TRAIT LOCUS 10; BMND10","url":"https://www.omim.org/entry/612113"},{"mim_id":"610830","title":"POLYOSTEOLYSIS-HYPEROSTOSIS SYNDROME","url":"https://www.omim.org/entry/610830"},{"mim_id":"607507","title":"PSORIATIC ARTHRITIS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/607507"},{"mim_id":"602643","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 11B; TNFRSF11B","url":"https://www.omim.org/entry/602643"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"},{"location":"Nucleoplasm","reliability":"Additional"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":192.4},{"tissue":"thyroid gland","ntpm":95.4}],"url":"https://www.proteinatlas.org/search/TNFRSF11B"},"hgnc":{"alias_symbol":["OCIF","TR1"],"prev_symbol":["OPG"]},"alphafold":{"accession":"O00300","domains":[{"cath_id":"2.10.50.10","chopping":"24-107","consensus_level":"medium","plddt":95.7445,"start":24,"end":107},{"cath_id":"2.10.50.10","chopping":"110-187","consensus_level":"medium","plddt":91.8129,"start":110,"end":187},{"cath_id":"-","chopping":"196-390","consensus_level":"medium","plddt":88.9079,"start":196,"end":390}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00300","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00300-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00300-F1-predicted_aligned_error_v6.png","plddt_mean":86.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TNFRSF11B","jax_strain_url":"https://www.jax.org/strain/search?query=TNFRSF11B"},"sequence":{"accession":"O00300","fasta_url":"https://rest.uniprot.org/uniprotkb/O00300.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00300/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00300"}},"corpus_meta":[{"pmid":"18395508","id":"PMC_18395508","title":"Functions of RANKL/RANK/OPG in bone modeling and remodeling.","date":"2008","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/18395508","citation_count":1318,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11713196","id":"PMC_11713196","title":"Minireview: the OPG/RANKL/RANK system.","date":"2001","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/11713196","citation_count":1046,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15561602","id":"PMC_15561602","title":"The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling.","date":"2004","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/15561602","citation_count":531,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22543469","id":"PMC_22543469","title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab.","date":"2012","source":"Nature reviews. Drug discovery","url":"https://pubmed.ncbi.nlm.nih.gov/22543469","citation_count":521,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33079279","id":"PMC_33079279","title":"Osteoclast differentiation by RANKL and OPG signaling pathways.","date":"2020","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33079279","citation_count":514,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25368616","id":"PMC_25368616","title":"Biology of the RANKL-RANK-OPG System in Immunity, Bone, and Beyond.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25368616","citation_count":487,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22092994","id":"PMC_22092994","title":"The RANKL-OPG system in clinical periodontology.","date":"2011","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/22092994","citation_count":265,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14969393","id":"PMC_14969393","title":"PTH differentially regulates expression of RANKL and OPG.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/14969393","citation_count":262,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17925190","id":"PMC_17925190","title":"The RANKL/RANK/OPG pathway.","date":"2007","source":"Current osteoporosis reports","url":"https://pubmed.ncbi.nlm.nih.gov/17925190","citation_count":256,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19419454","id":"PMC_19419454","title":"RANK/RANKL/OPG during orthodontic tooth movement.","date":"2009","source":"Orthodontics & craniofacial research","url":"https://pubmed.ncbi.nlm.nih.gov/19419454","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25004813","id":"PMC_25004813","title":"Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications.","date":"2014","source":"Current topics in microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/25004813","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15363860","id":"PMC_15363860","title":"RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis.","date":"2004","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/15363860","citation_count":192,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12189164","id":"PMC_12189164","title":"A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype.","date":"2002","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/12189164","citation_count":165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33389131","id":"PMC_33389131","title":"Discovery of the RANKL/RANK/OPG system.","date":"2021","source":"Journal of bone and mineral metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/33389131","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12469211","id":"PMC_12469211","title":"Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction.","date":"2003","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12469211","citation_count":158,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22113597","id":"PMC_22113597","title":"Rank/Rankl/opg: literature review.","date":"2011","source":"Acta reumatologica portuguesa","url":"https://pubmed.ncbi.nlm.nih.gov/22113597","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21840222","id":"PMC_21840222","title":"Type 1 regulatory T cells (Tr1) in autoimmunity.","date":"2011","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21840222","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19191757","id":"PMC_19191757","title":"Action of RANKL and OPG for osteoclastogenesis.","date":"2009","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/19191757","citation_count":130,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21893418","id":"PMC_21893418","title":"Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27.","date":"2011","source":"Seminars in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21893418","citation_count":129,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6308007","id":"PMC_6308007","title":"RNA polymerase pausing and transcript release at the lambda tR1 terminator in vitro.","date":"1983","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/6308007","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15557398","id":"PMC_15557398","title":"Local OPG gene transfer to periodontal tissue inhibits orthodontic tooth movement.","date":"2004","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/15557398","citation_count":108,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16407878","id":"PMC_16407878","title":"Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis.","date":"2006","source":"Nature clinical practice. Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/16407878","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18974013","id":"PMC_18974013","title":"Mechanical loading highly increases IL-6 production and decreases OPG expression by osteoblasts.","date":"2008","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/18974013","citation_count":105,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18200504","id":"PMC_18200504","title":"IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis.","date":"2008","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/18200504","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18707795","id":"PMC_18707795","title":"Pathophysiological roles of osteoprotegerin (OPG).","date":"2008","source":"European journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18707795","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28003377","id":"PMC_28003377","title":"IL-10 Receptor Signaling Is Essential for TR1 Cell Function In Vivo.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28003377","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16464170","id":"PMC_16464170","title":"Role of osteoprotegerin (OPG) in cancer.","date":"2006","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/16464170","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37893470","id":"PMC_37893470","title":"The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer.","date":"2023","source":"Medicina (Kaunas, Lithuania)","url":"https://pubmed.ncbi.nlm.nih.gov/37893470","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19762475","id":"PMC_19762475","title":"Modulation of OPG, RANK and RANKL by human chondrocytes and their implication during osteoarthritis.","date":"2009","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19762475","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9790989","id":"PMC_9790989","title":"Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.","date":"1998","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9790989","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26765224","id":"PMC_26765224","title":"Blimp-1-Dependent IL-10 Production by Tr1 Cells Regulates TNF-Mediated Tissue Pathology.","date":"2016","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/26765224","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14672344","id":"PMC_14672344","title":"Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/14672344","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20163972","id":"PMC_20163972","title":"RANK/RANKL/OPG role in distraction osteogenesis.","date":"2010","source":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/20163972","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19398882","id":"PMC_19398882","title":"New perspective in osteoarthritis: the OPG and RANKL system as a potential therapeutic target?","date":"2009","source":"The Keio journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/19398882","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35693934","id":"PMC_35693934","title":"The Roles of RANK/RANKL/OPG in Cardiac, Skeletal, and Smooth Muscles in Health and Disease.","date":"2022","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/35693934","citation_count":68,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12847240","id":"PMC_12847240","title":"Induction of autoantigen-specific Th2 and Tr1 regulatory T cells and modulation of autoimmune diabetes.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12847240","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28635957","id":"PMC_28635957","title":"ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells.","date":"2017","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/28635957","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31119697","id":"PMC_31119697","title":"Probiotics and bone disorders: the role of RANKL/RANK/OPG pathway.","date":"2019","source":"Aging clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/31119697","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19934002","id":"PMC_19934002","title":"Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant.","date":"2009","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/19934002","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14726762","id":"PMC_14726762","title":"Specialization in tolerance: innate CD(4+)CD(25+) versus acquired TR1 and TH3 regulatory T cells.","date":"2004","source":"Transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/14726762","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"14981127","id":"PMC_14981127","title":"Opg, Rank, and Rankl in tooth development: co-ordination of odontogenesis and osteogenesis.","date":"2004","source":"Journal of dental research","url":"https://pubmed.ncbi.nlm.nih.gov/14981127","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27683580","id":"PMC_27683580","title":"Tr1-Like T Cells - An Enigmatic Regulatory T Cell Lineage.","date":"2016","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27683580","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32850393","id":"PMC_32850393","title":"Targeting the RANKL/RANK/OPG Axis for Cancer Therapy.","date":"2020","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32850393","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31811910","id":"PMC_31811910","title":"FoxO3 reverses 5-fluorouracil resistance in human colorectal cancer cells by inhibiting the Nrf2/TR1 signaling pathway.","date":"2019","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/31811910","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21903966","id":"PMC_21903966","title":"Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability.","date":"2011","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/21903966","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16479591","id":"PMC_16479591","title":"Leptin effect on RANKL and OPG expression in MC3T3-E1 osteoblasts.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16479591","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25984250","id":"PMC_25984250","title":"B Cell Production of Both OPG and RANKL is Significantly Increased in Aged Mice.","date":"2014","source":"The Open bone journal","url":"https://pubmed.ncbi.nlm.nih.gov/25984250","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25112376","id":"PMC_25112376","title":"RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy.","date":"2014","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/25112376","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28937598","id":"PMC_28937598","title":"The Effect of RANKL/OPG Balance on Reducing Implant Complications.","date":"2017","source":"Journal of functional biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/28937598","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27200369","id":"PMC_27200369","title":"Roles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular Disease.","date":"2016","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/27200369","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24743232","id":"PMC_24743232","title":"A gain of function mutation in TNFRSF11B encoding osteoprotegerin causes osteoarthritis with chondrocalcinosis.","date":"2014","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/24743232","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17388729","id":"PMC_17388729","title":"Identification of sex-specific associations between polymorphisms of the osteoprotegerin gene, TNFRSF11B, and Paget's disease of bone.","date":"2007","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/17388729","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20714810","id":"PMC_20714810","title":"Levels of osteoprotegerin (OPG) and receptor activator for nuclear factor kappa B ligand (RANKL) in serum: are they of any help?","date":"2010","source":"Wiener medizinische Wochenschrift (1946)","url":"https://pubmed.ncbi.nlm.nih.gov/20714810","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32398963","id":"PMC_32398963","title":"TNFRSF11B activates Wnt/β-catenin signaling and promotes gastric cancer progression.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32398963","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21259010","id":"PMC_21259010","title":"The expression of RANKL and OPG in the various grades of osteoarthritic cartilage.","date":"2011","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/21259010","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16343827","id":"PMC_16343827","title":"TNFRSF11B gene variants and bone mineral density in postmenopausal women in Malta.","date":"2005","source":"Maturitas","url":"https://pubmed.ncbi.nlm.nih.gov/16343827","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36288653","id":"PMC_36288653","title":"Equol exerts a protective effect on postmenopausal osteoporosis by upregulating OPG/RANKL pathway.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36288653","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19565568","id":"PMC_19565568","title":"DNA methylation and histone modification regulate silencing of OPG during tumor progression.","date":"2009","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19565568","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30443169","id":"PMC_30443169","title":"Influence of DNA methylation on the expression of OPG/RANKL in primary osteoporosis.","date":"2018","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30443169","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22965192","id":"PMC_22965192","title":"Association between TNFRSF11B gene polymorphisms and history of ischemic stroke in Italian diabetic patients.","date":"2012","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22965192","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21994215","id":"PMC_21994215","title":"Functional polymorphisms within the TNFRSF11B (osteoprotegerin) gene increase the risk for low bone mineral density.","date":"2011","source":"Journal of molecular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/21994215","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16826057","id":"PMC_16826057","title":"Expression of RANKL and OPG in middle ear cholesteatoma tissue.","date":"2006","source":"The Laryngoscope","url":"https://pubmed.ncbi.nlm.nih.gov/16826057","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15615493","id":"PMC_15615493","title":"Heritable disorders of the RANKL/OPG/RANK signaling pathway.","date":"2004","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/15615493","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27576059","id":"PMC_27576059","title":"Daidzein increases OPG/RANKL ratio and suppresses IL-6 in MG-63 osteoblast cells.","date":"2016","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/27576059","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16137499","id":"PMC_16137499","title":"CSF-1, RANKL and OPG regulate osteoclastogenesis during murine tooth eruption.","date":"2005","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/16137499","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15615495","id":"PMC_15615495","title":"RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.","date":"2004","source":"Journal of musculoskeletal & neuronal interactions","url":"https://pubmed.ncbi.nlm.nih.gov/15615495","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27038462","id":"PMC_27038462","title":"Differentiation and Characterization of Tr1 Cells.","date":"2016","source":"Current protocols in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/27038462","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20633673","id":"PMC_20633673","title":"Association between radiographic hand osteoarthritis and RANKL, OPG and inflammatory markers.","date":"2010","source":"Osteoarthritis and cartilage","url":"https://pubmed.ncbi.nlm.nih.gov/20633673","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18228207","id":"PMC_18228207","title":"Role of OPG/RANKL/RANK axis on the vasculature.","date":"2008","source":"Histology and histopathology","url":"https://pubmed.ncbi.nlm.nih.gov/18228207","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32000757","id":"PMC_32000757","title":"Substance P participates in periodontitis by upregulating HIF-1α and RANKL/OPG ratio.","date":"2020","source":"BMC oral health","url":"https://pubmed.ncbi.nlm.nih.gov/32000757","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24283361","id":"PMC_24283361","title":"Association between seven common OPG genetic polymorphisms and osteoporosis risk: a meta-analysis.","date":"2013","source":"DNA and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/24283361","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30819183","id":"PMC_30819183","title":"Adiponectin regulates bone mass in AIS osteopenia via RANKL/OPG and IL6 pathway.","date":"2019","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/30819183","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17711477","id":"PMC_17711477","title":"Prevalence of OPG and IL-1 gene polymorphisms in chronic periodontitis.","date":"2007","source":"Journal of clinical periodontology","url":"https://pubmed.ncbi.nlm.nih.gov/17711477","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19995704","id":"PMC_19995704","title":"OPG/RANK/RANKL signaling system and its significance in nephrology.","date":"2009","source":"Folia histochemica et cytobiologica","url":"https://pubmed.ncbi.nlm.nih.gov/19995704","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34171336","id":"PMC_34171336","title":"The role of osteoprotegerin (OPG) in fibrosis: its potential as a biomarker and/or biological target for the treatment of fibrotic diseases.","date":"2021","source":"Pharmacology & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/34171336","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15777670","id":"PMC_15777670","title":"An intermediate form of juvenile Paget's disease caused by a truncating TNFRSF11B mutation.","date":"2005","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/15777670","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20059964","id":"PMC_20059964","title":"TGFbeta inducible early gene-1 directly binds to, and represses, the OPG promoter in osteoblasts.","date":"2010","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/20059964","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21938481","id":"PMC_21938481","title":"Bisphosphonates modulate the expression of OPG and M-CSF in hMSC-derived osteoblasts.","date":"2011","source":"Clinical oral investigations","url":"https://pubmed.ncbi.nlm.nih.gov/21938481","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18592139","id":"PMC_18592139","title":"Imbalance of RANK, RANKL and OPG expression during tibial fracture repair in diabetic rats.","date":"2008","source":"Journal of molecular histology","url":"https://pubmed.ncbi.nlm.nih.gov/18592139","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33989379","id":"PMC_33989379","title":"The role of TNFRSF11B in development of osteoarthritic cartilage.","date":"2022","source":"Rheumatology (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/33989379","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18367263","id":"PMC_18367263","title":"OPG, RANK and RANK ligand expression in thyroid lesions.","date":"2008","source":"Regulatory peptides","url":"https://pubmed.ncbi.nlm.nih.gov/18367263","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17352649","id":"PMC_17352649","title":"Juvenile Paget's disease: the second reported, oldest patient is homozygous for the TNFRSF11B \"Balkan\" mutation (966_969delTGACinsCTT), which elevates circulating immunoreactive osteoprotegerin levels.","date":"2007","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/17352649","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31097613","id":"PMC_31097613","title":"TRAIL, OPG, and TWEAK in kidney disease: biomarkers or therapeutic targets?","date":"2019","source":"Clinical science (London, England : 1979)","url":"https://pubmed.ncbi.nlm.nih.gov/31097613","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20602239","id":"PMC_20602239","title":"Serum RANKL, osteoprotegerin (OPG), and RANKL/OPG ratio in nephrotic children.","date":"2010","source":"Pediatric nephrology (Berlin, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/20602239","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18928898","id":"PMC_18928898","title":"Expression of bone resorption regulators (RANK, RANKL, and OPG) in odontogenic tumors.","date":"2008","source":"Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics","url":"https://pubmed.ncbi.nlm.nih.gov/18928898","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21411255","id":"PMC_21411255","title":"TNFRSF11B gene polymorphisms 1181G > C and 245T > G as well as haplotype CT influence bone mineral density in postmenopausal women.","date":"2011","source":"Maturitas","url":"https://pubmed.ncbi.nlm.nih.gov/21411255","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28576140","id":"PMC_28576140","title":"RANK/RANKL/OPG system in the intervertebral disc.","date":"2017","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/28576140","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20497460","id":"PMC_20497460","title":"Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling.","date":"2010","source":"European journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/20497460","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31578655","id":"PMC_31578655","title":"Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.","date":"2019","source":"Clinical & experimental metastasis","url":"https://pubmed.ncbi.nlm.nih.gov/31578655","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16117195","id":"PMC_16117195","title":"Osteoprotegerin (OPG) and receptor activator of NF-kB ligand (RANK-L) serum levels in patients on chronic hemodialysis.","date":"2005","source":"Journal of endocrinological investigation","url":"https://pubmed.ncbi.nlm.nih.gov/16117195","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20033478","id":"PMC_20033478","title":"RANKL and OPG mRNA level after non-surgical periodontal treatment.","date":"2010","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/20033478","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31921469","id":"PMC_31921469","title":"Lactobacillus pentosus Modulates Immune Response by Inducing IL-10 Producing Tr1 Cells.","date":"2019","source":"Immune network","url":"https://pubmed.ncbi.nlm.nih.gov/31921469","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22638612","id":"PMC_22638612","title":"Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene.","date":"2012","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/22638612","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35991310","id":"PMC_35991310","title":"Roles of type 1 regulatory T (Tr1) cells in allergen-specific immunotherapy.","date":"2022","source":"Frontiers in allergy","url":"https://pubmed.ncbi.nlm.nih.gov/35991310","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27430581","id":"PMC_27430581","title":"Pioglitazone affects the OPG/RANKL/RANK system and increase osteoclastogenesis.","date":"2016","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/27430581","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20920282","id":"PMC_20920282","title":"TNFRSF11B computational development network construction and analysis between frontal cortex of HIV encephalitis (HIVE) and HIVE-control patients.","date":"2010","source":"Journal of inflammation (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/20920282","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28604806","id":"PMC_28604806","title":"Prostaglandin E2 inhibits Tr1 cell differentiation through suppression of c-Maf.","date":"2017","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/28604806","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21849854","id":"PMC_21849854","title":"OPG/RANKL/RANK pathway as a therapeutic target in cancer.","date":"2011","source":"Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21849854","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35274217","id":"PMC_35274217","title":"Mesenchymal Stem Cells Alleviate Inflammatory Bowel Disease Via Tr1 Cells.","date":"2022","source":"Stem cell reviews and reports","url":"https://pubmed.ncbi.nlm.nih.gov/35274217","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35754337","id":"PMC_35754337","title":"Piezo1-mediated fluid shear stress promotes OPG and inhibits RANKL via NOTCH3 in MLO-Y4 osteocytes.","date":"2022","source":"Channels (Austin, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35754337","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9108485","id":"PMC_9108485","title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.","date":"1997","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9108485","citation_count":3964,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9520411","id":"PMC_9520411","title":"Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9520411","citation_count":3272,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9950424","id":"PMC_9950424","title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis.","date":"1999","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/9950424","citation_count":2612,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9573043","id":"PMC_9573043","title":"osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9573043","citation_count":1928,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9492069","id":"PMC_9492069","title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.","date":"1998","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/9492069","citation_count":982,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9603945","id":"PMC_9603945","title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9603945","citation_count":974,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22504420","id":"PMC_22504420","title":"Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22504420","citation_count":958,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17634140","id":"PMC_17634140","title":"Biology of RANK, RANKL, and osteoprotegerin.","date":"2007","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17634140","citation_count":691,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9168977","id":"PMC_9168977","title":"Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.","date":"1997","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/9168977","citation_count":619,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19801982","id":"PMC_19801982","title":"Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies.","date":"2009","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19801982","citation_count":552,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18455228","id":"PMC_18455228","title":"Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study.","date":"2008","source":"Lancet (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/18455228","citation_count":522,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18445777","id":"PMC_18445777","title":"Multiple genetic loci for bone mineral density and fractures.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18445777","citation_count":485,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15564564","id":"PMC_15564564","title":"Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin.","date":"2004","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/15564564","citation_count":383,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12124406","id":"PMC_12124406","title":"Osteoprotegerin deficiency and juvenile Paget's disease.","date":"2002","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12124406","citation_count":296,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21980299","id":"PMC_21980299","title":"A genome-wide meta-analysis of six type 1 diabetes cohorts identifies multiple associated loci.","date":"2011","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21980299","citation_count":260,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22705116","id":"PMC_22705116","title":"New insights into osteoclastogenic signaling mechanisms.","date":"2012","source":"Trends in endocrinology and metabolism: TEM","url":"https://pubmed.ncbi.nlm.nih.gov/22705116","citation_count":252,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9434163","id":"PMC_9434163","title":"Characterization of a novel TNF-like ligand and recently described TNF ligand and TNF receptor superfamily genes and their constitutive and inducible expression in hematopoietic and non-hematopoietic cells.","date":"1997","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9434163","citation_count":238,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14734048","id":"PMC_14734048","title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification.","date":"2004","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/14734048","citation_count":225,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11912131","id":"PMC_11912131","title":"Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.","date":"2002","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/11912131","citation_count":222,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17895323","id":"PMC_17895323","title":"CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.","date":"2007","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17895323","citation_count":195,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12351414","id":"PMC_12351414","title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12351414","citation_count":189,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15538968","id":"PMC_15538968","title":"Following a TRAIL: update on a ligand and its five receptors.","date":"2004","source":"Cell research","url":"https://pubmed.ncbi.nlm.nih.gov/15538968","citation_count":187,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"18305214","id":"PMC_18305214","title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.","date":"2008","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/18305214","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12364326","id":"PMC_12364326","title":"Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12364326","citation_count":177,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15292354","id":"PMC_15292354","title":"Localization of osteoprotegerin, tumor necrosis factor-related apoptosis-inducing ligand, and receptor activator of nuclear factor-kappaB ligand in Mönckeberg's sclerosis and atherosclerosis.","date":"2004","source":"The Journal of clinical endocrinology and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15292354","citation_count":169,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":48804,"output_tokens":4344,"usd":0.105786},"stage2":{"model":"claude-opus-4-6","input_tokens":7851,"output_tokens":3138,"usd":0.176558},"total_usd":0.796379,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":62560,"output_tokens":8128,"usd":0.1548},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":11933,"output_tokens":7193,"usd":0.359235}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1998,\n      \"finding\": \"Osteoprotegerin (OPG/OCIF, encoded by TNFRSF11B) directly inhibits bone-resorbing activity of isolated mature osteoclasts by disrupting F-actin ring formation through an ODF-independent mechanism; a 140 kDa OPG-binding protein was detected on the osteoclast plasma membrane.\",\n      \"method\": \"In vitro bone resorption assay with purified mature osteoclasts (>95% purity), F-actin ring staining, binding assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro functional assay with purified osteoclasts, receptor binding identified, multiple orthogonal readouts\",\n      \"pmids\": [\"9790989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"OPG (TNFRSF11B) functions as a soluble decoy receptor that binds RANKL, preventing RANKL from binding to its signaling receptor RANK on osteoclast lineage cells, thereby blocking osteoclast differentiation and activation.\",\n      \"method\": \"Genetic mouse models (OPG knockout → osteoporosis; OPG overexpression → osteopetrosis), ligand-binding assays, osteoclast differentiation assays\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — replicated across multiple labs with genetic models and binding assays; foundational discovery replicated independently\",\n      \"pmids\": [\"11713196\", \"18395508\", \"14969393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A 3-bp in-frame deletion in exon 3 of TNFRSF11B (loss of an aspartate residue) causes loss of OPG function: recombinant mutant OPG expressed in human epithelial kidney cells fails to suppress bone resorption in vitro, establishing this as an inactivating mutation underlying idiopathic hyperphosphatasia.\",\n      \"method\": \"Mutant recombinant protein expression in HEK cells, in vitro bone resorption assay, genetic linkage and sequencing\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted mutant protein in vitro with functional readout (bone resorption suppression assay), directly linking genotype to molecular mechanism\",\n      \"pmids\": [\"12189164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Homozygous mutations in TNFRSF11B causing idiopathic hyperphosphatasia cluster in the cysteine-rich ligand-binding domain (exons encoding RANKL-binding region); missense mutations at cysteine residues predict major disruption of RANKL binding and associate with severe phenotype, while C-terminal mutations predict milder disease, establishing a domain-function map for OPG.\",\n      \"method\": \"Genomic sequencing across nine families, genotype-phenotype correlation, structural prediction\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-family genetic study with systematic genotype-phenotype mapping; no direct in vitro mutagenesis for each variant but consistent with structural logic\",\n      \"pmids\": [\"14672344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A truncating TNFRSF11B mutation (insertion/deletion in exon 5, truncation at aa 325) deletes the C-terminal domain required for OPG homodimerization, reducing the capacity of the mutant protein to bind RANKL; absence of the C-terminal cysteine abolishes homodimerization as shown by Western blotting and ELISA after transient overexpression.\",\n      \"method\": \"Transient overexpression of wild-type and truncated OPG constructs, Western blotting, ELISA, functional RANKL-binding assay\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical demonstration that C-terminal domain is required for homodimerization and RANKL binding using recombinant mutant protein\",\n      \"pmids\": [\"15777670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The TNFRSF11B 'Balkan' frameshift mutation (966_969delTGACinsCTT) deletes 79 C-terminal amino acids including the cysteine required for OPG homodimerization, producing elevated circulating immunoreactive OPG (truncated monomer) and soluble RANKL, confirming that OPG homodimerization via the C-terminal cysteine is required for normal function.\",\n      \"method\": \"Sequencing of TNFRSF11B, serum ELISA for immunoreactive OPG and soluble RANKL, clinical correlation\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic and biochemical serum data consistent with molecular mechanism; no in vitro reconstitution but strong structural inference confirmed by protein measurement\",\n      \"pmids\": [\"17352649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TGFβ-inducible early gene-1 (TIEG/KLF10) directly binds to a 200 bp region of the OPG (TNFRSF11B) promoter containing two Sp-1 sites and represses OPG transcription in osteoblasts; TIEG knockout osteoblasts show increased OPG expression and reduced capacity to support osteoclastogenesis.\",\n      \"method\": \"Luciferase reporter assays, transient ChIP with TIEG-specific antibody, site-directed mutagenesis of Sp-1 sites, TIEG KO mouse calvarial osteoblasts, real-time PCR\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — ChIP demonstrates direct promoter binding, mutagenesis identifies specific Sp-1 elements, KO phenotype corroborates transcriptional regulation\",\n      \"pmids\": [\"20059964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"After OPG binds to cells expressing membranous RANKL, OPG undergoes internalization via the clathrin pathway followed by proteasomal and/or lysosomal degradation, and this internalization process reduces the half-life of RANKL.\",\n      \"method\": \"Cell-based internalization assay, pathway inhibitor studies (clathrin inhibition), RANKL half-life measurement\",\n      \"journal\": \"The Keio journal of medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic cell-based assay with pathway inhibitors identifying clathrin-dependent internalization; single lab\",\n      \"pmids\": [\"19398882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"OPG (TNFRSF11B product) acts as a decoy receptor for TRAIL (TNF-related apoptosis-inducing ligand) in addition to RANKL, thereby inhibiting TRAIL-induced apoptosis in tumor cells and potentially promoting tumor cell survival.\",\n      \"method\": \"Recombinant OPG binding assay with TRAIL, apoptosis assays in tumor cell lines\",\n      \"journal\": \"European journal of cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding and functional apoptosis assay establishing dual decoy receptor function; reviewed from multiple studies\",\n      \"pmids\": [\"18707795\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A heterozygous read-through gain-of-function mutation in TNFRSF11B (c.1205A>T; p.Stop402Leu) causes familial early-onset osteoarthritis with chondrocalcinosis; the mutant OPG shows enhanced capacity to inhibit osteoclastogenesis and bone resorption in a cell-based bone resorption assay.\",\n      \"method\": \"Exome sequencing, genotyping, linkage analysis, cell-based bone resorption assay comparing wild-type and mutant OPG\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional cell-based assay directly demonstrates gain-of-function effect of the mutation on bone resorption inhibition, supported by genetic data\",\n      \"pmids\": [\"24743232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Overexpression of TNFRSF11B in primary human articular chondrocytes in a 3D chondrogenic model upregulates MMP13, COL2A1, COL1A1, RUNX2, ASPN, OGN, and BMP6 (9-fold), promoting a chondrocyte-to-osteoblast transition, without altering RANK or RANKL expression, indicating TNFRSF11B acts via previously unknown downstream pathways in cartilage independent of the canonical OPG/RANK/RANKL triad.\",\n      \"method\": \"Lentiviral TNFRSF11B overexpression in primary chondrocytes, 3D in vitro chondrogenic model, RT-qPCR, immunohistochemistry, Alcian blue staining, ELISA, RNA-seq correlation\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct loss/gain-of-function in primary human cells with multiple orthogonal readouts; single lab\",\n      \"pmids\": [\"33989379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TNFRSF11B (OPG) promotes gastric cancer cell proliferation, migration, invasion, and inhibits apoptosis via direct binding to GSK-3β, increasing GSK-3β phosphorylation and activating Wnt/β-catenin signaling (increased nuclear β-catenin and downstream effectors).\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence for nuclear β-catenin, Western blot, in vitro and in vivo tumor assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP demonstrates direct binding to GSK-3β with functional downstream readouts; single lab\",\n      \"pmids\": [\"32398963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"OPG (TNFRSF11B product) produced by osteocytes plays an important role in maintenance of cortical and alveolar bone, as demonstrated using OPG gene-deficient mice.\",\n      \"method\": \"OPG gene knockout mouse model, bone phenotype analysis\",\n      \"journal\": \"Journal of bone and mineral metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct genetic knockout with defined skeletal phenotype; replicated finding\",\n      \"pmids\": [\"33079279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Local OPG gene transfer (plasmid pcDNA3.1-mOPG via HVJ envelope vector) to periodontal tissue inhibits RANKL-mediated osteoclastogenesis and suppresses orthodontic tooth movement in vivo, establishing that OPG neutralizes RANKL activity in vivo.\",\n      \"method\": \"In vivo rat orthodontic tooth movement model, OPG plasmid gene transfer, in vitro functional confirmation of OPG protein activity, histological osteoclast counting\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo gain-of-function gene transfer experiment with quantitative tooth movement and osteoclast phenotype readouts; functional protein validation in vitro\",\n      \"pmids\": [\"15557398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The TNFRSF11B promoter T allele (C950T polymorphism) shows significantly lower luciferase expression than the C allele in HeLa, COS-7, and RAW264.7 cell lines; an rs4876869 C allele causes exon skipping in pre-mRNA splicing, reducing full-length OPG transcript, linking these variants to reduced OPG expression and increased bone resorption risk.\",\n      \"method\": \"Luciferase reporter assay in multiple cell lines, exon-trapping vector splicing assay, sequencing\",\n      \"journal\": \"Journal of molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — direct functional promoter and splicing assays in multiple cell lines; single lab\",\n      \"pmids\": [\"21994215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"OPG-Fc (lacking the heparin-binding domain) treatment of OA chondrocytes significantly stimulates MMP-13 and PAR-2 production, indicating that OPG has a functional role in OA cartilage pathophysiology beyond its canonical RANKL decoy receptor activity.\",\n      \"method\": \"Recombinant OPG-Fc treatment of primary human OA chondrocytes, ELISA, flow cytometry for RANK and RANKL\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct pharmacological perturbation with defined cellular readout in primary human cells; single lab\",\n      \"pmids\": [\"19762475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"OPG silencing in nasopharyngeal carcinoma and other cancer cell lines is associated with promoter CpG hypermethylation and histone modifications (reduced H3K4me3, increased H3K27me3); administration of recombinant OPG reduces cancer cell growth through apoptosis.\",\n      \"method\": \"cDNA microarray, Q-RT-PCR, bisulfite sequencing, ChIP for histone marks, recombinant OPG apoptosis assay\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — epigenetic mechanism identified with ChIP and bisulfite sequencing; functional apoptosis assay with recombinant protein; single lab\",\n      \"pmids\": [\"19565568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In MLO-Y4 osteocytes, Piezo1-mediated fluid shear stress promotes OPG expression and inhibits RANKL expression via the NOTCH3 pathway; blockade of Piezo1 with GsMTx4 reverses these effects.\",\n      \"method\": \"Fluid shear stress exposure, Piezo1 blocker (GsMTx4), NOTCH3 pathway analysis, gene expression measurements\",\n      \"journal\": \"Channels (Austin, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mechanosensitive pathway experiment with pharmacological inhibition and pathway identification; single lab\",\n      \"pmids\": [\"35754337\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF11B encodes osteoprotegerin (OPG), a secreted homodimeric decoy receptor (requiring C-terminal cysteine for dimerization) that competitively binds RANKL to prevent RANKL–RANK interaction and thereby blocks osteoclast differentiation, activation, and survival; OPG also binds TRAIL to inhibit apoptosis, undergoes clathrin-mediated internalization and degradation upon RANKL binding (reducing RANKL half-life), and its transcription is directly repressed by KLF10/TIEG via Sp-1 elements in its promoter, while loss-of-function mutations in TNFRSF11B cause uncontrolled osteoclastogenesis (juvenile Paget's disease/idiopathic hyperphosphatasia) and gain-of-function mutations cause excessive osteoclast inhibition leading to osteoarthritis with chondrocalcinosis.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper and extract discoveries only from KEEP papers.\n\n**Classification summary:**\n- Papers about Tr1 cells (regulatory T cells) — EXCLUDE (alias collision: \"Tr1\" ≠ TNFRSF11B/OPG)\n- Paper [20] about lambda tR1 terminator — EXCLUDE (alias collision)\n- Paper [44] about TR1 = thioredoxin reductase 1 — EXCLUDE (alias collision)\n- Paper [96] TNFRSF11B computational network — EXCLUDE (purely computational, Tier 4 with no mechanistic findings)\n- MGC cDNA papers, oligo-capping papers — EXCLUDE (not mechanistic for TNFRSF11B)\n- All remaining papers about OPG/RANKL/RANK system — KEEP if mechanistic\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1997,\n      \"finding\": \"Osteoprotegerin (OPG/TNFRSF11B) was identified as a novel secreted glycoprotein member of the TNF receptor superfamily that inhibits osteoclast differentiation from precursor cells in a dose-dependent manner. Hepatic overexpression in transgenic mice caused osteopetrosis with decreased osteoclast numbers, and administration of recombinant OPG to normal mice replicated these effects. OPG also blocked ovariectomy-associated bone loss in rats.\",\n      \"method\": \"Transgenic mouse overexpression, recombinant protein administration in vivo, in vitro osteoclast differentiation assay\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal in vivo and in vitro methods in founding discovery paper, replicated broadly\",\n      \"pmids\": [\"9108485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"OPG/OCIF was purified from human fibroblast conditioned medium as a heparin-binding glycoprotein existing as a monomer (~60 kDa) and homodimer (~120 kDa). It specifically inhibited osteoclastogenesis driven by three distinct signaling pathways (vitamin D3, PTH, IL-11) without inhibiting mature osteoclast bone-resorbing activity, establishing it as a specific inhibitor of osteoclast development rather than function.\",\n      \"method\": \"Protein purification, in vitro osteoclastogenesis assay with multiple stimuli\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — purified protein with multiple functional assays, replicated by independent group\",\n      \"pmids\": [\"9168977\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"OPG/OCIF was shown to inhibit osteoclastogenesis by binding to a high-affinity site on osteoblastic stromal cells (ST2 line), blocking the cell-to-cell signal required for osteoclast progenitor differentiation. A single class of high-affinity OPG-binding sites appeared on ST2 cells in response to 1,25-dihydroxyvitamin D3, and an antibody blocking OPG binding to these sites abolished OPG's biological activity.\",\n      \"method\": \"Binding assay on stromal cells, antibody blockade, osteoclastogenesis coculture assay\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — receptor binding characterization with functional antibody blockade, replicated\",\n      \"pmids\": [\"9492069\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Osteoclast differentiation factor (ODF/RANKL) was identified as the ligand for OPG/OCIF by expression cloning from mouse stromal cell cDNA library. OPG abolished OCL formation induced by soluble ODF, establishing OPG as a decoy receptor that blocks RANKL-RANK signaling to prevent osteoclastogenesis.\",\n      \"method\": \"Expression cloning, recombinant protein functional assay, OPG neutralization of ODF activity\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ligand identified by expression cloning with direct functional neutralization, foundational paper\",\n      \"pmids\": [\"9520411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"OPG-deficient mice develop early-onset osteoporosis with severe trabecular and cortical bone porosity and high fracture incidence, demonstrating OPG is a critical regulator of postnatal bone mass. Unexpectedly, OPG-/- mice also develop medial calcification of the aorta and renal arteries, revealing OPG's role in protecting large arteries from calcification.\",\n      \"method\": \"Knockout mouse generation, skeletal phenotyping, histology, arterial pathology assessment\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function mouse model with defined skeletal and vascular phenotypes, highly replicated\",\n      \"pmids\": [\"9573043\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"OPG was identified as a receptor for the cytotoxic ligand TRAIL, binding TRAIL with an affinity of ~3 nM. OPG-Fc inhibits TRAIL-induced apoptosis of Jurkat cells, and conversely TRAIL blocks OPG's anti-osteoclastogenic activity, revealing cross-regulatory mechanisms between bone remodeling and apoptosis pathways.\",\n      \"method\": \"Binding affinity measurement (Fc-fusion proteins), TRAIL-induced apoptosis assay, competitive inhibition\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct binding affinity measured, functional competition assay, replicated extensively\",\n      \"pmids\": [\"9603945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"OCIF/OPG directly inhibits bone-resorbing activity of isolated mature osteoclasts in an ODF-independent manner. An OPG-binding protein of 140 kDa was detected on the osteoclast plasma membrane. OPG did not affect cathepsin K or carbonic anhydrase II mRNA levels but reduced/disrupted F-actin ring formation in osteoclasts, a cytoskeletal structure required for bone resorption.\",\n      \"method\": \"Isolated osteoclast bone resorption assay, ligand binding on osteoclast membrane, F-actin staining\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct functional assay on purified osteoclasts with mechanistic readout (F-actin ring disruption)\",\n      \"pmids\": [\"9790989\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Genetic deletion of OPGL (RANKL) in mice caused severe osteopetrosis and complete absence of osteoclasts, confirming OPG's ligand RANKL is an essential osteoclast differentiation factor in vivo and that the OPG/RANKL system is the dominant regulator of osteoclastogenesis.\",\n      \"method\": \"Gene knockout in mice, skeletal phenotyping, osteoclast enumeration\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo establishing pathway position, replicated and foundational\",\n      \"pmids\": [\"9950424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"A homozygous 3-bp in-frame deletion in exon 3 of TNFRSF11B (loss of aspartate residue) was found in patients with idiopathic hyperphosphatasia. Recombinant mutant OPG expressed in HEK cells was secreted but failed to suppress bone resorption in vitro, whereas wild-type OPG suppressed it, confirming this as an inactivating mutation affecting RANKL-binding function.\",\n      \"method\": \"Genetic sequencing, recombinant protein expression in HEK cells, in vitro bone resorption assay\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — functional mutagenesis validated in bone resorption assay, genotype-phenotype confirmed\",\n      \"pmids\": [\"12189164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Juvenile Paget's disease in two Navajo patients results from homozygous deletion of TNFRSF11B (~100 kb) at chromosome 8q24.2. Serum OPG was undetectable and soluble RANKL was markedly elevated, directly demonstrating that OPG deficiency causes uncontrolled RANKL-driven osteoclastogenesis and rapid bone turnover in humans.\",\n      \"method\": \"PCR and Southern blotting of genomic DNA, sequence-tagged site mapping, ELISA for serum OPG and sRANKL\",\n      \"journal\": \"The New England journal of medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complete gene deletion with direct measurement of OPG absence and RANKL elevation\",\n      \"pmids\": [\"12124406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"OPG is produced by prostate cancer cells and functions as a survival factor by inhibiting TRAIL-induced apoptosis. High endogenous OPG production correlated with resistance to TRAIL-induced apoptosis, and this protection was reversed by 100-fold molar excess of RANKL (which competes for OPG binding), establishing OPG as a cancer cell survival factor via TRAIL neutralization.\",\n      \"method\": \"TRAIL apoptosis assay, OPG ELISA, competitive inhibition with RANKL, multiple prostate cancer cell lines\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional assay with competitive reversal in multiple cell lines\",\n      \"pmids\": [\"11912131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Multiple myeloma cells bind, internalize, and degrade OPG through a mechanism dependent on OPG interaction with heparan sulfates on myeloma cell surfaces, providing a mechanism for reduced OPG levels in myeloma bone marrow and contributing to myeloma-associated bone destruction.\",\n      \"method\": \"OPG binding and internalization assays on myeloma cells, heparan sulfate competition, degradation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of OPG internalization with heparan sulfate dependence established\",\n      \"pmids\": [\"12351414\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"PTH stimulates RANKL gene transcription and mRNA stability while potently suppressing OPG mRNA in stromal/osteoblastic cells via protein kinase A (PKA) activation. The transcription factor CREB is required for PTH stimulation of RANKL; dominant-negative CREB and c-fos reduced PTH suppression of OPG, establishing a PKA-CREB pathway as the mechanism for PTH-mediated regulation of the RANKL/OPG axis.\",\n      \"method\": \"PKA inhibition, dominant-negative CREB/c-fos expression, luciferase reporter assay, mRNA stability assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple epistasis experiments with dominant-negative constructs establishing pathway mechanism\",\n      \"pmids\": [\"12364326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Homozygous mutations in TNFRSF11B were found in affected members of six of nine families with idiopathic hyperphosphatasia. Four of six mutations occurred in the cysteine-rich ligand-binding domain, predicted to disrupt OPG-RANKL binding. Cysteine missense mutations causing major disruption of the ligand-binding region correlated with severe phenotype, while non-cysteine or C-terminal mutations caused milder phenotypes, establishing a genotype-phenotype relationship for TNFRSF11B domain function.\",\n      \"method\": \"Genomic DNA sequencing, clinical phenotype correlation\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — genotype-phenotype mapping predicts domain function without direct in vitro reconstitution for all mutations\",\n      \"pmids\": [\"14672344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"PTH differentially regulates RANKL and OPG expression across osteoblast differentiation stages: PTH maximally inhibits OPG in early osteoblasts (day 14) and maximally upregulates RANKL in mature osteoblasts (days 21-28). PTH-induced changes in RANKL/OPG ratio at day 14 increased TRACP+ cell numbers 5.6-fold in coculture, demonstrating that stage-specific PTH regulation of RANKL and OPG has functional osteoclastogenic consequences.\",\n      \"method\": \"qRT-PCR at multiple osteoblast differentiation stages, osteoclast coculture assay with TRACP staining\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — quantitative gene expression across differentiation stages linked to functional osteoclastogenesis readout\",\n      \"pmids\": [\"14969393\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Local OPG gene transfer (via HVJ envelope vector carrying pcDNA3.1-mOPG) to the periodontal tissue of rats significantly inhibited osteoclastogenesis and reduced experimental orthodontic tooth movement, demonstrating that OPG protein produced locally can neutralize RANKL activity and block osteoclast-mediated bone resorption in vivo.\",\n      \"method\": \"In vivo gene transfer, OPG protein production confirmed in vitro, osteoclast enumeration, tooth movement measurement\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gene delivery with functional bone resorption and tooth movement readouts\",\n      \"pmids\": [\"15557398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"OPG and RANK show expression in both internal and external enamel epithelium and dental papilla mesenchyme during murine odontogenesis, while RANKL is expressed in pre-osteogenic mesenchymal cells near developing tooth germs. Addition of exogenous OPG to tooth primordia explant cultures delayed tooth development and reduced mineralization, establishing a functional role for OPG in coordinating odontogenesis and osteogenesis.\",\n      \"method\": \"In situ hybridization/expression analysis during odontogenesis, OPG addition to organ culture explants\",\n      \"journal\": \"Journal of dental research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — expression pattern with functional exogenous OPG treatment in explant culture\",\n      \"pmids\": [\"14981127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"RANKL stimulates matrix calcification, nodule formation, alkaline phosphatase activity, and expression of osteocalcin in cultured human aortic valve myofibroblasts, and increases DNA binding of cbfa-1. OPG expression is significantly lower in calcific aortic stenosis than controls, suggesting the RANKL-OPG pathway regulates valvular calcification by promoting osteoblast-like transition of valve cells.\",\n      \"method\": \"Immunohistochemistry on human valves, RANKL stimulation of cultured myofibroblasts, alkaline phosphatase assay, cbfa-1 DNA binding assay\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct RANKL stimulation with functional calcification and osteogenic gene readouts in primary cells\",\n      \"pmids\": [\"14734048\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"A truncating TNFRSF11B mutation (homozygous insertion/deletion in exon 5) predicts protein truncation at amino acid 325. Western blotting and ELISA after transient overexpression showed the mutant protein lacks homodimerization (C-terminal domain required for this) and has decreased RANKL-binding capacity, demonstrating that the C-terminal domain of OPG is required for homodimerization and full functional RANKL antagonism.\",\n      \"method\": \"Western blotting, ELISA, transient overexpression of wild-type vs. truncated OPG\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct biochemical demonstration that C-terminal truncation abolishes homodimerization and reduces RANKL binding\",\n      \"pmids\": [\"15777670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The TNFRSF11B 'Balkan' mutation (966_969delTGACinsCTT) deletes 79 C-terminal amino acids including a cysteine residue necessary for homodimerization. Despite elevated circulating immunoreactive OPG, the truncated monomer cannot form homodimers, and soluble RANKL is persistently elevated, demonstrating that OPG homodimerization via C-terminal cysteine is required for effective RANKL inhibition in vivo.\",\n      \"method\": \"TNFRSF11B sequencing, serum OPG and sRANKL ELISA, structural prediction of homodimerization requirement\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — in vivo biochemical data (elevated monomeric OPG with impaired function) consistent with homodimerization requirement\",\n      \"pmids\": [\"17352649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"IL-6 and PGE2 produced by mechanically loaded osteoblasts induce a decrease in OPG expression (but not RANKL), and IL-6 neutralizing antibodies and piroxicam block this OPG decrease, establishing that mechanical compression-induced IL-6 and PGE2 downregulate OPG to increase the RANKL/OPG ratio in osteoblasts.\",\n      \"method\": \"Compression model of primary osteoblasts, neutralizing antibodies, COX inhibitor, real-time PCR, ELISA\",\n      \"journal\": \"Osteoarthritis and cartilage\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — cytokine neutralization identifies IL-6/PGE2 as mediators of OPG suppression under mechanical load\",\n      \"pmids\": [\"18974013\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"OPG binds membranous RANKL on cells and undergoes internalization through the clathrin pathway prior to proteasomal and/or lysosomal degradation. This OPG internalization process reduces the half-life of RANKL, revealing a reciprocal mechanism by which OPG-RANKL binding leads to co-degradation of both molecules.\",\n      \"method\": \"Internalization assay, clathrin pathway inhibition, degradation assays\",\n      \"journal\": \"The Keio journal of medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — mechanistic pathway (clathrin-mediated internalization) identified for OPG-RANKL complex\",\n      \"pmids\": [\"19398882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"OPG-Fc (OPG without the heparin-binding domain) treatment of OA chondrocytes significantly stimulated MMP-13 and PAR-2 production, revealing that OPG has RANKL-independent signaling in chondrocytes that promotes catabolic factor expression, a pathway distinct from its role in bone remodeling.\",\n      \"method\": \"OPG-Fc treatment of primary human OA chondrocytes, cytokine measurement by ELISA, flow cytometry for RANK/RANKL\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct OPG treatment with specific catabolic readouts in primary human cells\",\n      \"pmids\": [\"19762475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DNA methylation silences OPG expression in cancer cells: OPG promoter CpG dinucleotides are highly methylated in OPG-silenced cancer cell lines, with reduced H3K4me3 and increased H3K27me3 at the OPG gene. Recombinant OPG reduced cancer cell growth through apoptosis, establishing epigenetic repression as a mechanism of OPG silencing in carcinoma.\",\n      \"method\": \"Bisulfite sequencing, ChIP for histone modifications, recombinant OPG apoptosis assay, cDNA microarray\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — epigenetic mechanism identified with ChIP and functional rOPG apoptosis assay\",\n      \"pmids\": [\"19565568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TGFβ-inducible early gene-1 (TIEG/KLF10) directly binds to the OPG promoter and represses its transcription in osteoblasts. Transient ChIP assays showed TIEG occupancy at the OPG promoter, and site-directed mutagenesis identified two Sp-1 binding sites within a 200 bp region as required for TIEG-mediated repression, explaining why TIEG KO osteoblasts have increased OPG and reduced osteoclastogenesis support.\",\n      \"method\": \"ChIP assay, luciferase reporter with OPG promoter deletion constructs, site-directed mutagenesis, TIEG KO osteoblasts\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — ChIP demonstrates direct binding, mutagenesis identifies specific Sp-1 sites, supported by KO model\",\n      \"pmids\": [\"20059964\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"A heterozygous read-through mutation (c.1205A>T; p.Stop402Leu) in TNFRSF11B was identified in a family with dominantly inherited early-onset osteoarthritis with chondrocalcinosis. The mutant OPG showed enhanced capacity to inhibit osteoclastogenesis and bone resorption in a bone resorption cell-based assay, establishing this as a gain-of-function mutation in TNFRSF11B that causes OA.\",\n      \"method\": \"Exome sequencing, linkage analysis, bone resorption cell-based assay comparing wild-type vs. mutant OPG\",\n      \"journal\": \"Annals of the rheumatic diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional assay demonstrates gain-of-function, supported by family genetics\",\n      \"pmids\": [\"24743232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DNA methylation inversely regulates OPG and RANKL expression in osteoporotic bone: OPG promoter CpG methylation is higher and OPG expression lower in osteoporotic fracture bone, while RANKL promoter methylation is lower and RANKL expression higher, demonstrating that promoter methylation is a major epigenetic switch controlling the RANKL/OPG ratio in bone pathophysiology.\",\n      \"method\": \"Bisulfite sequencing of promoter CpG islands, qRT-PCR of OPG and RANKL in bone biopsies\",\n      \"journal\": \"International journal of medical sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — correlative methylation-expression analysis in human bone tissue without functional validation\",\n      \"pmids\": [\"30443169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TNFRSF11B overexpression in gastric cancer cells promotes proliferation, migration, invasion, and tumorigenesis. Mechanistically, TNFRSF11B directly binds GSK-3β (detected by co-immunoprecipitation), upregulates GSK-3β phosphorylation, and consequently increases nuclear β-catenin and downstream Wnt/β-catenin target gene expression, identifying a non-canonical RANKL-independent oncogenic signaling role for TNFRSF11B.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence for nuclear β-catenin, Western blotting, in vitro and in vivo tumor assays\",\n      \"journal\": \"International journal of biological sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP identifies GSK-3β interaction with functional Wnt pathway readout, single lab\",\n      \"pmids\": [\"32398963\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"TNFRSF11B overexpression in primary human articular chondrocytes (3D chondrogenic model) strongly upregulates MMP13, COL2A1, COL1A1, RUNX2, ASPN, OGN, and BMP6 (9-fold), while RANK and RANKL expression remained unchanged, indicating TNFRSF11B drives chondrocyte-to-osteoblast transition in OA cartilage through previously unknown downstream pathways independent of the OPG/RANK/RANKL triad.\",\n      \"method\": \"Lentiviral overexpression in primary chondrocytes, 3D chondrogenic culture, RT-qPCR, immunohistochemistry, ELISA, Alcian blue staining\",\n      \"journal\": \"Rheumatology (Oxford, England)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — lentiviral overexpression in 3D primary cell model with multiple downstream readouts, single lab\",\n      \"pmids\": [\"33989379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Fluid shear stress (FSS) promotes OPG expression and inhibits RANKL expression in MLO-Y4 osteocytes via Piezo1 mechanosensitive ion channel and NOTCH3 signaling. Blocking Piezo1 with GsMTx4 reversed FSS effects on OPG and RANKL, establishing a Piezo1-NOTCH3 pathway as a mechanotransduction mechanism regulating OPG production.\",\n      \"method\": \"Fluid shear stress apparatus, Piezo1 blocker (GsMTx4), RT-PCR and protein expression in osteocyte cell line\",\n      \"journal\": \"Channels (Austin, Tex.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — pharmacological blockade of Piezo1 with OPG/RANKL readout, single lab with mechanistic pathway identification\",\n      \"pmids\": [\"35754337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"OPG and TRAIL co-localize at sites of vascular calcification in Mönckeberg's sclerosis and atherosclerosis, with OPG expressed surrounding calcified areas in medial and neointimal layers where apoptosis also occurs, suggesting OPG is expressed at vascular calcification sites to regulate both apoptosis (via TRAIL) and osteoclast-like differentiation.\",\n      \"method\": \"Immunohistochemistry, in situ hybridization, in situ ligation apoptosis assay on human arterial specimens\",\n      \"journal\": \"The Journal of clinical endocrinology and metabolism\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — localization study in human tissue with mechanistic implication but no direct functional experiment\",\n      \"pmids\": [\"15292354\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Myeloma-derived DKK1 (a Wnt inhibitor) abolishes Wnt3a-induced OPG mRNA and protein production by mouse and human osteoblasts, while simultaneously enhancing RANKL expression, providing a molecular mechanism by which myeloma cells disrupt the Wnt-regulated OPG/RANKL balance to promote osteoclastogenesis and bone lesions.\",\n      \"method\": \"Recombinant DKK1 treatment, coculture of osteoblasts with MM cells, Wnt3a stimulation, OPG/RANKL mRNA and protein measurement, bone marrow sera from MM patients\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (recombinant protein, coculture, patient samples) establishing DKK1→Wnt→OPG mechanism\",\n      \"pmids\": [\"18305214\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TNFRSF11B (osteoprotegerin/OPG) is a secreted homodimeric decoy receptor of the TNF receptor superfamily that inhibits osteoclastogenesis by binding RANKL (preventing RANKL-RANK interaction) and also neutralizes TRAIL-induced apoptosis; its activity is regulated by PTH via a PKA-CREB pathway, by transcription factor TIEG1 (KLF10) binding Sp-1 sites in its promoter, by epigenetic promoter methylation, by Wnt signaling, and by mechanical load via Piezo1-NOTCH3; OPG homodimerization through C-terminal cysteine residues is required for full RANKL-binding activity, loss-of-function TNFRSF11B mutations cause juvenile Paget's disease/idiopathic hyperphosphatasia through unrestrained RANKL-driven osteoclastogenesis, and beyond bone OPG also protects arteries from calcification, while in cancer contexts TNFRSF11B can activate Wnt/β-catenin signaling through direct GSK-3β interaction and drive chondrocyte-to-osteoblast transition through RANK/RANKL-independent downstream pathways.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TNFRSF11B encodes osteoprotegerin (OPG), a secreted decoy receptor that is a central negative regulator of osteoclast biology and bone resorption. OPG functions primarily by binding RANKL and preventing its interaction with the signaling receptor RANK on osteoclast-lineage cells, thereby blocking osteoclast differentiation, activation, and survival; OPG also directly inhibits mature osteoclast activity by disrupting F-actin ring formation through an ODF-independent mechanism involving a 140 kDa osteoclast surface protein [PMID:9790989, PMID:11713196]. Homodimerization via a C-terminal cysteine is required for efficient RANKL binding, and upon engagement with membrane-bound RANKL, OPG is internalized through clathrin-mediated endocytosis and degraded, simultaneously reducing RANKL half-life [PMID:15777670, PMID:19398882]. Loss-of-function mutations in TNFRSF11B cause idiopathic hyperphosphatasia (juvenile Paget's disease) through unopposed osteoclastogenesis, while a heterozygous gain-of-function stop-loss mutation causes familial early-onset osteoarthritis with chondrocalcinosis due to excessive osteoclast inhibition [PMID:12189164, PMID:24743232].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"The initial discovery that OPG acts directly on mature osteoclasts — not only on their precursors — established that OPG has a cell-autonomous inhibitory activity on bone resorption mediated through disruption of actin ring organization and a specific 140 kDa surface-binding protein.\",\n      \"evidence\": \"In vitro bone resorption assay with >95% purified osteoclasts, F-actin staining, and binding assay\",\n      \"pmids\": [\"9790989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Identity of the 140 kDa osteoclast-surface OPG-binding protein was not determined\",\n        \"Mechanism by which OPG disrupts F-actin ring formation independent of ODF/RANKL was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Genetic models definitively established OPG as the physiological soluble decoy receptor for RANKL, demonstrating that the OPG/RANKL/RANK axis is the master regulatory system for osteoclastogenesis: OPG knockout causes osteoporosis and overexpression causes osteopetrosis.\",\n      \"evidence\": \"OPG-knockout and OPG-overexpressing transgenic mice with complementary bone phenotypes, ligand-binding assays\",\n      \"pmids\": [\"11713196\", \"18395508\", \"14969393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis for OPG–RANKL interaction was not defined\",\n        \"Relative contribution of OPG from different cell types (osteoblasts vs. osteocytes) was unknown\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identification of a loss-of-function TNFRSF11B mutation causing idiopathic hyperphosphatasia linked the gene to a Mendelian bone disease and demonstrated that cysteine-rich domain integrity is essential for OPG's RANKL-neutralizing activity.\",\n      \"evidence\": \"3-bp in-frame deletion in exon 3, recombinant mutant OPG expressed in HEK cells fails to suppress bone resorption in vitro\",\n      \"pmids\": [\"12189164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Precise biophysical consequence of aspartate deletion on protein folding or RANKL binding affinity was not measured\",\n        \"Whether residual OPG function exists in vivo was not determined\"\n      ]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Systematic genotype-phenotype mapping across nine families established a domain-function hierarchy: mutations in the N-terminal cysteine-rich RANKL-binding domain produce severe disease, while C-terminal mutations yield milder phenotypes.\",\n      \"evidence\": \"Genomic sequencing of TNFRSF11B across nine idiopathic hyperphosphatasia families with genotype-phenotype correlation\",\n      \"pmids\": [\"14672344\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No in vitro mutagenesis was performed for each variant to directly measure RANKL binding\",\n        \"Structural modeling was predictive rather than experimentally validated\"\n      ]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Biochemical reconstitution resolved a key question about OPG quaternary structure: the C-terminal cysteine is required for homodimerization, and loss of dimerization reduces RANKL-binding capacity.\",\n      \"evidence\": \"Overexpression of wild-type vs. truncated OPG constructs, Western blot and ELISA demonstrating loss of dimerization and reduced RANKL binding\",\n      \"pmids\": [\"15777670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Stoichiometry of the OPG dimer–RANKL trimer complex was not defined\",\n        \"Whether monomeric OPG retains any residual RANKL-neutralizing function at physiological concentrations was unclear\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Establishing OPG as a dual decoy receptor — for both RANKL and TRAIL — expanded its functional repertoire beyond bone to anti-apoptotic signaling, particularly in tumor cell survival.\",\n      \"evidence\": \"Recombinant OPG binding assay with TRAIL and apoptosis assays in tumor cell lines\",\n      \"pmids\": [\"18707795\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Physiological relevance of OPG–TRAIL interaction in normal tissues was not established\",\n        \"Relative affinity of OPG for TRAIL versus RANKL was not directly compared under identical conditions\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"The discovery that OPG undergoes clathrin-dependent internalization and degradation upon binding membrane-bound RANKL revealed a mechanism by which OPG simultaneously neutralizes and depletes RANKL, acting as a ligand sink.\",\n      \"evidence\": \"Cell-based internalization assay with clathrin pathway inhibitors, RANKL half-life measurement\",\n      \"pmids\": [\"19398882\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether this internalization occurs in vivo at physiologically relevant OPG concentrations was not tested\",\n        \"Sorting signals on OPG or RANKL mediating clathrin-dependent endocytosis were not identified\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"OPG-Fc treatment of OA chondrocytes induced MMP-13 and PAR-2, establishing that OPG has RANKL-independent signaling roles in cartilage that contribute to osteoarthritis pathophysiology.\",\n      \"evidence\": \"Recombinant OPG-Fc treatment of primary human OA chondrocytes, ELISA and flow cytometry\",\n      \"pmids\": [\"19762475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The receptor or signaling pathway mediating OPG's effects on chondrocytes was not identified\",\n        \"Whether this effect occurs with full-length OPG (with heparin-binding domain) was not tested\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identification of KLF10/TIEG as a direct transcriptional repressor of OPG via Sp-1 sites established a TGFβ-responsive mechanism for downregulating OPG in osteoblasts, linking TGFβ signaling to osteoclastogenesis.\",\n      \"evidence\": \"ChIP with TIEG antibody on OPG promoter, Sp-1 site mutagenesis in luciferase reporters, TIEG-KO osteoblasts showing increased OPG\",\n      \"pmids\": [\"20059964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether TIEG/KLF10 repression of OPG is the primary mechanism of TGFβ-induced bone resorption in vivo was not determined\",\n        \"Other transcriptional regulators competing at the same Sp-1 sites were not characterized\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Discovery of a gain-of-function stop-loss mutation demonstrated that excessive OPG activity causes familial osteoarthritis with chondrocalcinosis, revealing that OPG dosage must be tightly regulated for joint as well as bone homeostasis.\",\n      \"evidence\": \"Exome sequencing of affected family, linkage analysis, cell-based bone resorption assay comparing wild-type and p.Stop402Leu mutant OPG\",\n      \"pmids\": [\"24743232\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which the extended OPG protein causes chondrocalcinosis (calcium pyrophosphate deposition) was not elucidated\",\n        \"Whether the extended C-terminus affects OPG dimerization, TRAIL binding, or novel interactions was not tested\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Overexpression studies in primary chondrocytes revealed OPG drives a chondrocyte-to-osteoblast transition via upregulation of MMP13, RUNX2, and BMP6 without altering RANK or RANKL, indicating non-canonical signaling pathways downstream of OPG in cartilage.\",\n      \"evidence\": \"Lentiviral TNFRSF11B overexpression in 3D chondrogenic model of primary human chondrocytes, RT-qPCR, immunohistochemistry, RNA-seq\",\n      \"pmids\": [\"33989379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The receptor and signaling intermediates mediating OPG's non-canonical effects in chondrocytes remain unidentified\",\n        \"Whether GSK-3β binding (described in gastric cancer) is relevant in chondrocytes was not addressed\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The receptor or signaling pathway through which OPG exerts its RANKL/RANK-independent effects on chondrocytes and osteoclasts (140 kDa binding partner, cartilage signaling, GSK-3β interaction) remains undefined, as does the structural basis for the OPG–RANKL interaction at atomic resolution.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"Identity of the 140 kDa osteoclast surface OPG-binding protein is still unknown\",\n        \"No crystal or cryo-EM structure of the OPG–RANKL complex exists in the timeline\",\n        \"In vivo relevance of OPG–GSK-3β interaction reported in gastric cancer has not been validated in independent systems\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [1, 4, 8, 13]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 8]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [1, 4, 5, 13]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 8, 11]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [8, 16]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 2, 13]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFSF11\",\n      \"TNFSF10\",\n      \"GSK3B\",\n      \"KLF10\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"TNFRSF11B (osteoprotegerin/OPG) is a secreted homodimeric decoy receptor of the TNF receptor superfamily that functions as a master negative regulator of osteoclastogenesis by sequestering RANKL and preventing its engagement with RANK on osteoclast precursors [PMID:9108485, PMID:9520411]. OPG also binds TRAIL with nanomolar affinity and inhibits TRAIL-induced apoptosis, linking bone remodeling to cell survival signaling in both normal and cancer contexts [PMID:9603945, PMID:11912131]. Homodimerization through C-terminal cysteine residues is required for full RANKL-binding activity, and OPG transcription is regulated by a PKA-CREB pathway downstream of PTH, by the transcriptional repressor TIEG/KLF10 acting through Sp-1 sites, by Wnt signaling, by promoter CpG methylation, and by mechanotransduction via Piezo1-NOTCH3 [PMID:15777670, PMID:12364326, PMID:20059964, PMID:18305214, PMID:35754337]. Loss-of-function mutations in TNFRSF11B cause juvenile Paget's disease (idiopathic hyperphosphatasia) through unrestrained RANKL-driven osteoclastogenesis, and OPG-deficient mice additionally develop arterial calcification, establishing OPG as a critical regulator of both bone mass and vascular integrity [PMID:12124406, PMID:9573043].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"The discovery that OPG is a secreted TNF receptor superfamily member that inhibits osteoclast differentiation in vitro and causes osteopetrosis when overexpressed in vivo established the existence of a soluble osteoclastogenesis inhibitor.\",\n      \"evidence\": \"Transgenic mouse overexpression, recombinant protein administration, and in vitro osteoclast differentiation assays; independently confirmed by purification from fibroblast conditioned medium\",\n      \"pmids\": [\"9108485\", \"9168977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of OPG's ligand was unknown\", \"Mechanism of osteoclastogenesis inhibition (direct vs. indirect) was unresolved\", \"Physiological relevance of endogenous OPG was not yet tested by loss-of-function\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of RANKL as the OPG ligand, and the demonstration that OPG binds TRAIL, established OPG as a dual decoy receptor integrating bone remodeling and apoptosis pathways.\",\n      \"evidence\": \"Expression cloning identified ODF/RANKL as OPG's osteoblast-expressed ligand; independent binding studies showed OPG binds TRAIL at ~3 nM and blocks TRAIL-induced apoptosis\",\n      \"pmids\": [\"9520411\", \"9603945\", \"9492069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether OPG-TRAIL interaction has physiological significance in vivo was unclear\", \"Relative affinities and competitive dynamics between RANKL and TRAIL binding to OPG were not fully quantified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"OPG knockout mice developing severe osteoporosis and arterial calcification demonstrated that endogenous OPG is essential for maintaining both bone mass and vascular integrity in vivo.\",\n      \"evidence\": \"OPG-/- mice with skeletal phenotyping and arterial histopathology\",\n      \"pmids\": [\"9573043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of OPG-mediated vascular protection was unknown\", \"Whether arterial calcification reflects direct OPG action on vascular cells or indirect bone-vascular coupling was unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Beyond blocking osteoclast differentiation, OPG was shown to directly inhibit bone-resorbing activity of mature osteoclasts by disrupting F-actin ring formation, via a 140 kDa binding protein on the osteoclast surface, revealing a post-differentiation function.\",\n      \"evidence\": \"Isolated osteoclast bone resorption assay with F-actin staining and ligand-binding detection\",\n      \"pmids\": [\"9790989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the 140 kDa OPG-binding protein on osteoclasts was not determined\", \"Whether this direct osteoclast effect is RANKL-dependent or independent was not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Human genetic studies linked loss-of-function TNFRSF11B mutations to juvenile Paget's disease, with complete gene deletion causing undetectable serum OPG and elevated RANKL, providing definitive proof that OPG is the critical RANKL antagonist in human bone homeostasis.\",\n      \"evidence\": \"Genomic deletion mapping, point mutation identification, serum OPG/sRANKL ELISA, and functional testing of mutant OPG in bone resorption assays\",\n      \"pmids\": [\"12124406\", \"12189164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full genotype-phenotype spectrum across different TNFRSF11B domains was incomplete\", \"Whether heterozygous carriers have intermediate bone phenotypes was not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The PTH-PKA-CREB pathway was identified as a major transcriptional regulator of the RANKL/OPG ratio, with PTH suppressing OPG through CREB-dependent mechanisms, explaining how hormonal signals modulate osteoclastogenesis via OPG.\",\n      \"evidence\": \"PKA inhibition, dominant-negative CREB/c-fos constructs, and reporter assays in osteoblastic cells; differentiation-stage analysis showed maximal OPG suppression in early osteoblasts\",\n      \"pmids\": [\"12364326\", \"14969393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CREB binding to the OPG promoter was not demonstrated by ChIP\", \"Whether other PTH-responsive transcription factors contribute was unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"OPG was found to function as a cancer cell survival factor by neutralizing TRAIL-induced apoptosis in prostate cancer, while myeloma cells actively degrade OPG via heparan sulfate-dependent internalization, revealing pathological exploitation of OPG in cancer.\",\n      \"evidence\": \"TRAIL apoptosis assays with RANKL competition in prostate cancer lines; OPG binding/internalization and degradation assays on myeloma cells\",\n      \"pmids\": [\"11912131\", \"12351414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether OPG-mediated TRAIL neutralization is relevant to other cancer types in vivo was untested\", \"Structural basis for OPG-heparan sulfate interaction was unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Truncation mutations removing the C-terminal domain abolished OPG homodimerization and reduced RANKL-binding capacity, establishing that C-terminal cysteine-mediated dimerization is required for full functional activity.\",\n      \"evidence\": \"Western blotting and ELISA of wild-type vs. truncated OPG after transient expression; confirmed by Balkan mutation analysis showing elevated monomeric OPG with impaired function in vivo\",\n      \"pmids\": [\"15777670\", \"17352649\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of the OPG homodimer was lacking\", \"Precise stoichiometry of OPG-RANKL complex was not determined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Wnt signaling was identified as a positive regulator of OPG production in osteoblasts, with myeloma-derived DKK1 abolishing Wnt3a-induced OPG expression while enhancing RANKL, providing a molecular mechanism for myeloma bone disease.\",\n      \"evidence\": \"Recombinant DKK1 and Wnt3a treatment of osteoblasts, coculture with myeloma cells, and patient bone marrow sera analysis\",\n      \"pmids\": [\"18305214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific Wnt pathway components (TCF/LEF binding sites) control OPG transcription was not mapped\", \"Whether other Wnt antagonists similarly suppress OPG was untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"TIEG/KLF10 was shown to directly bind the OPG promoter at Sp-1 sites and repress transcription, identifying a specific transcription factor–promoter interaction that fine-tunes OPG levels in osteoblasts.\",\n      \"evidence\": \"ChIP assay demonstrating TIEG occupancy, luciferase reporter with deletion constructs, and site-directed mutagenesis of Sp-1 sites\",\n      \"pmids\": [\"20059964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIEG regulation of OPG operates in non-osteoblast lineages was unknown\", \"Interaction with other Sp-1 site-binding factors was not examined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A gain-of-function read-through mutation in TNFRSF11B causing dominantly inherited early-onset osteoarthritis with chondrocalcinosis expanded the disease spectrum beyond loss-of-function bone disease, revealing that excessive OPG activity also has pathological consequences.\",\n      \"evidence\": \"Exome sequencing with linkage analysis, and functional bone resorption assay showing enhanced anti-resorptive activity of mutant OPG\",\n      \"pmids\": [\"24743232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which enhanced OPG activity causes chondrocalcinosis was not determined\", \"Whether the extended C-terminal sequence gains new binding properties was untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A RANKL-independent oncogenic function was identified in which TNFRSF11B directly binds GSK-3β, enhances its phosphorylation, and activates Wnt/β-catenin signaling in gastric cancer cells.\",\n      \"evidence\": \"Co-immunoprecipitation of OPG with GSK-3β, nuclear β-catenin quantification, and in vitro/in vivo tumor assays\",\n      \"pmids\": [\"32398963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GSK-3β interaction awaits reciprocal validation and domain mapping\", \"Whether this occurs in non-cancer cells is unknown\", \"Mechanism by which a secreted protein accesses intracellular GSK-3β was not explained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanotransduction inputs were connected to OPG regulation through the Piezo1-NOTCH3 axis in osteocytes, and RANKL-independent downstream effects of OPG overexpression in chondrocytes (driving osteoblast-like gene programs) were identified, broadening OPG's functional repertoire beyond RANKL sequestration.\",\n      \"evidence\": \"Fluid shear stress with Piezo1 blocker GsMTx4 in osteocyte cell line; lentiviral OPG overexpression in 3D primary chondrocyte culture with RT-qPCR for osteogenic markers\",\n      \"pmids\": [\"35754337\", \"33989379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NOTCH3 pathway intermediates connecting Piezo1 to OPG transcription were not mapped\", \"The receptor mediating RANKL-independent OPG signaling in chondrocytes is unknown\", \"In vivo validation of the Piezo1-OPG axis in bone loading is lacking\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of OPG homodimerization and RANKL/TRAIL dual binding, the identity of the receptor mediating RANKL-independent OPG signaling in chondrocytes and vascular cells, and the mechanism by which secreted OPG accesses intracellular GSK-3β in cancer contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of the OPG homodimer or OPG-RANKL complex exists\", \"RANKL-independent OPG receptor in chondrocytes/vasculature is unidentified\", \"GSK-3β interaction mechanism requires validation that OPG is internalized or acts before secretion\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 3, 5, 6]},\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [3, 5]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [3, 5, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 4, 9, 15]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": []},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 27, 31]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 10, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 13, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFSF11\",\n      \"TNFSF10\",\n      \"GSK3B\",\n      \"PIEZO1\",\n      \"KLF10\",\n      \"DKK1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway entries — I accidentally included a GO term in the pathway slot. Let me correct:\n\n```json\n{\n  \"mechanistic_narrative\": \"TNFRSF11B (osteoprotegerin/OPG) is a secreted homodimeric decoy receptor of the TNF receptor superfamily that functions as a master negative regulator of osteoclastogenesis by sequestering RANKL and preventing its engagement with RANK on osteoclast precursors [PMID:9108485, PMID:9520411]. OPG also binds TRAIL with nanomolar affinity and inhibits TRAIL-induced apoptosis, linking bone remodeling to cell survival signaling in both normal and cancer contexts [PMID:9603945, PMID:11912131]. Homodimerization through C-terminal cysteine residues is required for full RANKL-binding activity, and OPG transcription is regulated by a PKA-CREB pathway downstream of PTH, by the transcriptional repressor TIEG/KLF10 acting through Sp-1 sites, by Wnt signaling, by promoter CpG methylation, and by mechanotransduction via Piezo1-NOTCH3 [PMID:15777670, PMID:12364326, PMID:20059964, PMID:18305214, PMID:35754337]. Loss-of-function mutations in TNFRSF11B cause juvenile Paget's disease (idiopathic hyperphosphatasia) through unrestrained RANKL-driven osteoclastogenesis, and OPG-deficient mice additionally develop arterial calcification, establishing OPG as a critical regulator of both bone mass and vascular integrity [PMID:12124406, PMID:9573043].\",\n  \"teleology\": [\n    {\n      \"year\": 1997,\n      \"claim\": \"The discovery that OPG is a secreted TNF receptor superfamily member that inhibits osteoclast differentiation in vitro and causes osteopetrosis when overexpressed in vivo established the existence of a soluble osteoclastogenesis inhibitor.\",\n      \"evidence\": \"Transgenic mouse overexpression, recombinant protein administration, and in vitro osteoclast differentiation assays; independently confirmed by purification from fibroblast conditioned medium\",\n      \"pmids\": [\"9108485\", \"9168977\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of OPG's ligand was unknown\", \"Mechanism of osteoclastogenesis inhibition (direct vs. indirect) was unresolved\", \"Physiological relevance of endogenous OPG was not yet tested by loss-of-function\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Identification of RANKL as the OPG ligand, and the demonstration that OPG binds TRAIL, established OPG as a dual decoy receptor integrating bone remodeling and apoptosis pathways.\",\n      \"evidence\": \"Expression cloning identified ODF/RANKL as OPG's osteoblast-expressed ligand; independent binding studies showed OPG binds TRAIL at ~3 nM and blocks TRAIL-induced apoptosis\",\n      \"pmids\": [\"9520411\", \"9603945\", \"9492069\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether OPG-TRAIL interaction has physiological significance in vivo was unclear\", \"Relative affinities and competitive dynamics between RANKL and TRAIL binding to OPG were not fully quantified\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"OPG knockout mice developing severe osteoporosis and arterial calcification demonstrated that endogenous OPG is essential for maintaining both bone mass and vascular integrity in vivo.\",\n      \"evidence\": \"OPG-/- mice with skeletal phenotyping and arterial histopathology\",\n      \"pmids\": [\"9573043\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of OPG-mediated vascular protection was unknown\", \"Whether arterial calcification reflects direct OPG action on vascular cells or indirect bone-vascular coupling was unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Beyond blocking osteoclast differentiation, OPG was shown to directly inhibit bone-resorbing activity of mature osteoclasts by disrupting F-actin ring formation, via a 140 kDa binding protein on the osteoclast surface, revealing a post-differentiation function.\",\n      \"evidence\": \"Isolated osteoclast bone resorption assay with F-actin staining and ligand-binding detection\",\n      \"pmids\": [\"9790989\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the 140 kDa OPG-binding protein on osteoclasts was not determined\", \"Whether this direct osteoclast effect is RANKL-dependent or independent was not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Human genetic studies linked loss-of-function TNFRSF11B mutations to juvenile Paget's disease, with complete gene deletion causing undetectable serum OPG and elevated RANKL, providing definitive proof that OPG is the critical RANKL antagonist in human bone homeostasis.\",\n      \"evidence\": \"Genomic deletion mapping, point mutation identification, serum OPG/sRANKL ELISA, and functional testing of mutant OPG in bone resorption assays\",\n      \"pmids\": [\"12124406\", \"12189164\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full genotype-phenotype spectrum across different TNFRSF11B domains was incomplete\", \"Whether heterozygous carriers have intermediate bone phenotypes was not established\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"The PTH-PKA-CREB pathway was identified as a major transcriptional regulator of the RANKL/OPG ratio, with PTH suppressing OPG through CREB-dependent mechanisms, explaining how hormonal signals modulate osteoclastogenesis via OPG.\",\n      \"evidence\": \"PKA inhibition, dominant-negative CREB/c-fos constructs, and reporter assays in osteoblastic cells; differentiation-stage analysis showed maximal OPG suppression in early osteoblasts\",\n      \"pmids\": [\"12364326\", \"14969393\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct CREB binding to the OPG promoter was not demonstrated by ChIP\", \"Whether other PTH-responsive transcription factors contribute was unclear\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"OPG was found to function as a cancer cell survival factor by neutralizing TRAIL-induced apoptosis in prostate cancer, while myeloma cells actively degrade OPG via heparan sulfate-dependent internalization, revealing pathological exploitation of OPG in cancer.\",\n      \"evidence\": \"TRAIL apoptosis assays with RANKL competition in prostate cancer lines; OPG binding/internalization and degradation assays on myeloma cells\",\n      \"pmids\": [\"11912131\", \"12351414\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether OPG-mediated TRAIL neutralization is relevant to other cancer types in vivo was untested\", \"Structural basis for OPG-heparan sulfate interaction was unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Truncation mutations removing the C-terminal domain abolished OPG homodimerization and reduced RANKL-binding capacity, establishing that C-terminal cysteine-mediated dimerization is required for full functional activity.\",\n      \"evidence\": \"Western blotting and ELISA of wild-type vs. truncated OPG after transient expression; confirmed by Balkan mutation analysis showing elevated monomeric OPG with impaired function in vivo\",\n      \"pmids\": [\"15777670\", \"17352649\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Crystal structure of the OPG homodimer was lacking\", \"Precise stoichiometry of OPG-RANKL complex was not determined\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Wnt signaling was identified as a positive regulator of OPG production in osteoblasts, with myeloma-derived DKK1 abolishing Wnt3a-induced OPG expression while enhancing RANKL, providing a molecular mechanism for myeloma bone disease.\",\n      \"evidence\": \"Recombinant DKK1 and Wnt3a treatment of osteoblasts, coculture with myeloma cells, and patient bone marrow sera analysis\",\n      \"pmids\": [\"18305214\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Which specific Wnt pathway components (TCF/LEF binding sites) control OPG transcription was not mapped\", \"Whether other Wnt antagonists similarly suppress OPG was untested\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"TIEG/KLF10 was shown to directly bind the OPG promoter at Sp-1 sites and repress transcription, identifying a specific transcription factor–promoter interaction that fine-tunes OPG levels in osteoblasts.\",\n      \"evidence\": \"ChIP assay demonstrating TIEG occupancy, luciferase reporter with deletion constructs, and site-directed mutagenesis of Sp-1 sites\",\n      \"pmids\": [\"20059964\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether TIEG regulation of OPG operates in non-osteoblast lineages was unknown\", \"Interaction with other Sp-1 site-binding factors was not examined\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"A gain-of-function read-through mutation in TNFRSF11B causing dominantly inherited early-onset osteoarthritis with chondrocalcinosis expanded the disease spectrum beyond loss-of-function bone disease, revealing that excessive OPG activity also has pathological consequences.\",\n      \"evidence\": \"Exome sequencing with linkage analysis, and functional bone resorption assay showing enhanced anti-resorptive activity of mutant OPG\",\n      \"pmids\": [\"24743232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which enhanced OPG activity causes chondrocalcinosis was not determined\", \"Whether the extended C-terminal sequence gains new binding properties was untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"A RANKL-independent oncogenic function was identified in which TNFRSF11B directly binds GSK-3β, enhances its phosphorylation, and activates Wnt/β-catenin signaling in gastric cancer cells.\",\n      \"evidence\": \"Co-immunoprecipitation of OPG with GSK-3β, nuclear β-catenin quantification, and in vitro/in vivo tumor assays\",\n      \"pmids\": [\"32398963\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GSK-3β interaction awaits reciprocal validation and domain mapping\", \"Whether this occurs in non-cancer cells is unknown\", \"Mechanism by which a secreted protein accesses intracellular GSK-3β was not explained\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Mechanotransduction inputs were connected to OPG regulation through the Piezo1-NOTCH3 axis in osteocytes, and RANKL-independent downstream effects of OPG overexpression in chondrocytes (driving osteoblast-like gene programs) were identified, broadening OPG's functional repertoire beyond RANKL sequestration.\",\n      \"evidence\": \"Fluid shear stress with Piezo1 blocker GsMTx4 in osteocyte cell line; lentiviral OPG overexpression in 3D primary chondrocyte culture with RT-qPCR for osteogenic markers\",\n      \"pmids\": [\"35754337\", \"33989379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"NOTCH3 pathway intermediates connecting Piezo1 to OPG transcription were not mapped\", \"The receptor mediating RANKL-independent OPG signaling in chondrocytes is unknown\", \"In vivo validation of the Piezo1-OPG axis in bone loading is lacking\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of OPG homodimerization and RANKL/TRAIL dual binding, the identity of the receptor mediating RANKL-independent OPG signaling in chondrocytes and vascular cells, and the mechanism by which secreted OPG accesses intracellular GSK-3β in cancer contexts.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal structure of the OPG homodimer or OPG-RANKL complex exists\", \"RANKL-independent OPG receptor in chondrocytes/vasculature is unidentified\", \"GSK-3β interaction mechanism requires validation that OPG is internalized or acts before secretion\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 3, 5, 6]},\n      {\"term_id\": \"GO:0140313\", \"supporting_discovery_ids\": [3, 5, 10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 4, 9, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 27, 31]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [5, 10, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 9, 13, 25]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"TNFSF11\",\n      \"TNFSF10\",\n      \"GSK3B\",\n      \"KLF10\",\n      \"DKK1\",\n      \"NOTCH3\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}